<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<title>GRADE: A arte de julgar evid√™ncias</title>
<link href="https://fonts.googleapis.com" rel="preconnect"/>
<link crossorigin="" href="https://fonts.gstatic.com" rel="preconnect"/>
<link href="https://fonts.googleapis.com/css2?family=Cormorant+Garamond:ital,wght@0,400;0,600;0,700;1,400;1,600&amp;family=Source+Sans+Pro:wght@300;400;600;700&amp;display=swap" rel="stylesheet"/>
<style>
    :root {
      --navy: #1E2761;
      --deep-navy: #141B3D;
      --gold: #D4AF37;
      --cream: #FAF8F5;
      --light-cream: #FFFFFF;
      --text: #2D3748;
      --light-text: #718096;
      --red: #C53030;
      --green: #22c55e;
      --teal: #0f766e;
      --purple: #7c3aed;
      --orange: #f59e0b;
      --transition: 0.5s cubic-bezier(0.4, 0, 0.2, 1);
    }

    * { margin: 0; padding: 0; box-sizing: border-box; }
    html, body {
      height: 100%;
      font-family: 'Source Sans Pro', sans-serif;
      background: var(--deep-navy);
      color: var(--cream);
    }

    .course-container { display: flex; height: 100vh; overflow: hidden; }

    /* Skip Link for Accessibility */
    .skip-link {
      position: absolute;
      top: -40px;
      left: 0;
      background: var(--gold);
      color: var(--navy);
      padding: 8px 16px;
      z-index: 10000;
      text-decoration: none;
      font-weight: 600;
    }
    .skip-link:focus { top: 0; }

    /* ====== SIDEBAR ====== */
    .sidebar {
      width: 300px;
      background: linear-gradient(180deg, var(--deep-navy) 0%, #0a0f1a 100%);
      border-right: 1px solid rgba(212,175,55,0.2);
      display: flex;
      flex-direction: column;
      flex-shrink: 0;
    }

    .sidebar-header {
      padding: 1.25rem;
      border-bottom: 1px solid rgba(212,175,55,0.2);
      text-align: center;
    }
    .sidebar-header h1 {
      font-family: 'Cormorant Garamond', Georgia, serif;
      font-size: 1.3rem;
      font-weight: 700;
      color: var(--gold);
    }
    .sidebar-header p {
      font-size: 0.75rem;
      color: rgba(255,255,255,0.6);
    }

    /* Gamification Stats Panel */
    .stats-panel {
      padding: 1rem;
      background: rgba(212,175,55,0.1);
      border-bottom: 1px solid rgba(212,175,55,0.2);
    }
    .level-display {
      display: flex;
      align-items: center;
      gap: 0.75rem;
      margin-bottom: 0.75rem;
    }
    .level-badge {
      width: 48px;
      height: 48px;
      background: linear-gradient(135deg, var(--gold), #f0c040);
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 1.5rem;
      box-shadow: 0 2px 8px rgba(212,175,55,0.4);
    }
    .level-info { flex: 1; }
    .level-title { font-weight: 700; font-size: 0.9rem; color: var(--gold); }
    .level-subtitle { font-size: 0.7rem; color: rgba(255,255,255,0.6); }
    .xp-bar {
      height: 8px;
      background: rgba(255,255,255,0.1);
      border-radius: 4px;
      overflow: hidden;
      margin-top: 0.5rem;
    }
    .xp-fill {
      height: 100%;
      background: linear-gradient(90deg, var(--gold), var(--orange));
      border-radius: 4px;
      transition: width 0.5s ease;
    }
    .xp-text {
      font-size: 0.65rem;
      color: rgba(255,255,255,0.5);
      text-align: right;
      margin-top: 0.25rem;
    }
    .quick-stats {
      display: grid;
      grid-template-columns: repeat(3, 1fr);
      gap: 0.5rem;
      margin-top: 0.75rem;
    }
    .quick-stat {
      background: rgba(0,0,0,0.2);
      padding: 0.5rem;
      border-radius: 6px;
      text-align: center;
    }
    .quick-stat-value {
      font-size: 1.1rem;
      font-weight: 700;
      color: var(--gold);
    }
    .quick-stat-label {
      font-size: 0.6rem;
      color: rgba(255,255,255,0.5);
    }

    /* Course Progress */
    .course-progress {
      padding: 0.75rem 1rem;
      border-bottom: 1px solid rgba(212,175,55,0.2);
      background: rgba(0,0,0,0.2);
    }
    .course-progress-label {
      display: flex;
      justify-content: space-between;
      font-size: 0.7rem;
      color: rgba(255,255,255,0.6);
      margin-bottom: 0.35rem;
    }
    .course-progress-bar {
      height: 6px;
      background: rgba(255,255,255,0.1);
      border-radius: 3px;
      overflow: hidden;
    }
    .course-progress-fill {
      height: 100%;
      background: linear-gradient(90deg, var(--green), #22d3ee);
      border-radius: 3px;
      transition: width 0.5s ease;
    }

    .module-list { flex: 1; overflow-y: auto; padding: 0.5rem 0; }
    .module-item {
      display: flex;
      align-items: center;
      gap: 0.75rem;
      padding: 0.6rem 1rem;
      cursor: pointer;
      transition: all 0.2s;
      border-left: 3px solid transparent;
    }
    .module-item:hover { background: rgba(212,175,55,0.1); }
    .module-item.active { background: rgba(212,175,55,0.15); border-left-color: var(--gold); }
    .module-item.completed .module-number { background: var(--green); color: white; }
    .module-item.locked { opacity: 0.5; cursor: not-allowed; }
    .module-number {
      width: 26px;
      height: 26px;
      border-radius: 50%;
      background: rgba(255,255,255,0.1);
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 0.7rem;
      font-weight: 700;
      flex-shrink: 0;
    }
    .module-item.active .module-number { background: var(--gold); color: var(--navy); }
    .module-info { flex: 1; min-width: 0; }
    .module-title { font-size: 0.8rem; font-weight: 600; white-space: nowrap; overflow: hidden; text-overflow: ellipsis; }
    .module-subtitle { font-size: 0.65rem; color: rgba(255,255,255,0.5); }
    .module-xp { font-size: 0.6rem; color: var(--gold); }
    .module-time { font-size: 0.55rem; color: rgba(255,255,255,0.4); display: flex; align-items: center; gap: 0.25rem; margin-top: 0.15rem; }

    /* Badges Panel */
    .badges-panel {
      padding: 1rem;
      border-top: 1px solid rgba(212,175,55,0.2);
    }
    .badges-title { font-size: 0.75rem; font-weight: 600; color: var(--gold); margin-bottom: 0.5rem; }
    .badges-grid { display: flex; flex-wrap: wrap; gap: 0.35rem; }
    .badge-item {
      width: 32px;
      height: 32px;
      background: rgba(255,255,255,0.05);
      border: 2px solid rgba(255,255,255,0.1);
      border-radius: 6px;
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 0.9rem;
      opacity: 0.3;
      transition: all 0.3s;
      cursor: help;
      position: relative;
      padding: 0;
      color: inherit;
    }
    .badge-item.earned { opacity: 1; background: rgba(212,175,55,0.2); border-color: var(--gold); }
    .badge-item:hover::after {
      content: attr(title);
      position: absolute;
      bottom: 100%;
      left: 50%;
      transform: translateX(-50%);
      background: var(--navy);
      color: white;
      padding: 0.25rem 0.5rem;
      border-radius: 4px;
      font-size: 0.6rem;
      white-space: nowrap;
      z-index: 100;
    }

    /* ====== MAIN CONTENT ====== */
    .main-content { flex: 1; display: flex; flex-direction: column; overflow: hidden; }
    .content-header {
      padding: 0.75rem 1.5rem;
      background: rgba(0,0,0,0.3);
      border-bottom: 1px solid rgba(212,175,55,0.2);
      display: flex;
      align-items: center;
      justify-content: space-between;
    }
    .breadcrumb { font-size: 0.85rem; color: rgba(255,255,255,0.6); }
    .breadcrumb span { color: var(--gold); }
    .header-actions { display: flex; gap: 0.5rem; align-items: center; }
    .streak-display {
      display: flex;
      align-items: center;
      gap: 0.35rem;
      background: rgba(239,68,68,0.2);
      border: 1px solid rgba(239,68,68,0.4);
      padding: 0.35rem 0.75rem;
      border-radius: 20px;
      font-size: 0.8rem;
    }
    .streak-display.active { background: rgba(249,115,22,0.2); border-color: var(--orange); }
    .streak-flame { font-size: 1rem; }
    .streak-count { font-weight: 700; color: var(--orange); }

    .btn {
      padding: 0.5rem 1rem;
      border: 1px solid rgba(212,175,55,0.3);
      border-radius: 6px;
      background: rgba(255,255,255,0.05);
      color: var(--cream);
      font-size: 0.8rem;
      cursor: pointer;
      transition: all 0.2s;
    }
    .btn:hover { background: rgba(212,175,55,0.2); border-color: var(--gold); }
    .btn.primary { background: var(--gold); color: var(--navy); border-color: var(--gold); font-weight: 600; }

    .content-body { flex: 1; overflow: hidden; display: flex; }

    /* ====== SLIDES ====== */
    .slides-container { flex: 1; position: relative; overflow: hidden; }
    .module-slides { display: none; width: 100%; height: 100%; }
    .module-slides.active { display: block; }

    .slide {
      position: absolute;
      top: 0; left: 0;
      width: 100%; height: 100%;
      display: flex;
      flex-direction: column;
      justify-content: flex-start;
      align-items: center;
      padding: 2rem 2rem 4rem;
      opacity: 0;
      visibility: hidden;
      transition: opacity var(--transition), visibility var(--transition);
      overflow-y: auto;
    }
    .slide.active { opacity: 1; visibility: visible; }
    .slide.dark { background: var(--deep-navy); }
    .slide.light { background: var(--cream); color: var(--text); }
    .slide.black { background: #000; }
    .slide.red-bg { background: linear-gradient(135deg, #7f1d1d, #450a0a); }
    .slide.green-bg { background: linear-gradient(135deg, #14532d, #052e16); }
    .slide.purple-bg { background: linear-gradient(135deg, #4c1d95, #2e1065); }
    .slide.orange-bg { background: linear-gradient(135deg, #9a3412, #431407); }

    .slide-progress-bar {
      position: absolute;
      top: 0;
      left: 0;
      height: 3px;
      background: linear-gradient(90deg, var(--gold), var(--orange));
      transition: width 0.3s ease;
      z-index: 50;
    }

    .serif { font-family: 'Cormorant Garamond', Georgia, serif; }
    .title {
      font-family: 'Cormorant Garamond', Georgia, serif;
      font-size: clamp(1.8rem, 4vw, 3rem);
      font-weight: 700;
      margin-bottom: 1rem;
      line-height: 1.2;
      text-align: center;
    }
    .title.gold { color: var(--gold); }
    .title.navy { color: var(--navy); }
    .subtitle {
      font-size: clamp(0.9rem, 2vw, 1.3rem);
      color: rgba(255,255,255,0.7);
      margin-bottom: 1.5rem;
      text-align: center;
    }
    .slide.light .subtitle { color: var(--light-text); }

    .big-number {
      font-family: 'Cormorant Garamond', Georgia, serif;
      font-size: clamp(4rem, 12vw, 8rem);
      font-weight: 700;
      line-height: 1;
    }
    .big-number.gold { color: var(--gold); }
    .big-number.red { color: var(--red); }

    .refrain {
      font-family: 'Cormorant Garamond', Georgia, serif;
      font-size: clamp(1.3rem, 3vw, 2rem);
      font-style: italic;
      color: var(--gold);
      text-align: center;
      max-width: 700px;
    }

    .content { display: flex; flex-direction: column; align-items: center; width: 100%; max-width: 850px; }

    /* Cards */
    .card {
      background: var(--light-cream);
      border: 1px solid var(--gold);
      padding: 1.25rem 1.5rem;
      margin: 0.5rem 0;
      max-width: 750px;
      width: 100%;
      border-radius: 8px;
    }
    .card.navy-bg { background: var(--navy); color: var(--cream); }
    .card.red-border { border: 2px solid var(--red); }
    .card.green-border { border: 2px solid var(--green); }
    .card-label {
      font-size: 0.7rem;
      font-weight: 700;
      color: var(--gold);
      letter-spacing: 0.05em;
      margin-bottom: 0.4rem;
      text-transform: uppercase;
    }
    .card-text { font-size: 0.95rem; line-height: 1.6; }
    .card.navy-bg .card-text { color: var(--cream); }

    /* Story box */
    .story-box {
      background: linear-gradient(135deg, rgba(197,48,48,0.15), rgba(30,39,97,0.2));
      border-left: 4px solid var(--red);
      padding: 1.25rem;
      margin: 0.75rem 0;
      max-width: 750px;
      width: 100%;
      border-radius: 0 8px 8px 0;
    }
    .story-box.success { background: linear-gradient(135deg, rgba(34,197,94,0.15), rgba(30,39,97,0.2)); border-left-color: var(--green); }
    .story-box.warning { background: linear-gradient(135deg, rgba(245,158,11,0.15), rgba(30,39,97,0.2)); border-left-color: var(--orange); }
    .story-label {
      font-size: 0.7rem;
      font-weight: 700;
      letter-spacing: 0.1em;
      color: var(--red);
      margin-bottom: 0.4rem;
      text-transform: uppercase;
    }
    .story-box.success .story-label { color: var(--green); }
    .story-box.warning .story-label { color: var(--orange); }
    .story-text { font-size: 0.95rem; line-height: 1.6; }

    /* Epic Story Box */
    .story-box.epic {
      background: linear-gradient(135deg, rgba(20,27,61,0.95), rgba(0,0,0,0.9));
      border-left: 4px solid var(--gold);
      border-top: 1px solid rgba(212,175,55,0.3);
      border-right: 1px solid rgba(212,175,55,0.2);
      border-bottom: 1px solid rgba(212,175,55,0.2);
      padding: 1.5rem;
      position: relative;
    }
    .story-box.epic::before {
      content: '';
      position: absolute;
      top: 0;
      left: 0;
      right: 0;
      height: 2px;
      background: linear-gradient(90deg, var(--gold), transparent);
    }
    .story-box.epic .story-label { color: var(--gold); font-size: 0.65rem; letter-spacing: 0.15em; }
    .story-box.epic .story-text { font-family: 'Cormorant Garamond', Georgia, serif; font-size: 1.05rem; line-height: 1.7; }

    /* GRADE Certainty Colors */
    .grade-high { background: linear-gradient(135deg, rgba(34,197,94,0.2), rgba(30,39,97,0.2)); border-color: var(--green); }
    .grade-moderate { background: linear-gradient(135deg, rgba(59,130,246,0.2), rgba(30,39,97,0.2)); border-color: #3b82f6; }
    .grade-low { background: linear-gradient(135deg, rgba(245,158,11,0.2), rgba(30,39,97,0.2)); border-color: var(--orange); }
    .grade-very-low { background: linear-gradient(135deg, rgba(197,48,48,0.2), rgba(30,39,97,0.2)); border-color: var(--red); }

    .grade-badge {
      display: inline-block;
      padding: 0.25rem 0.75rem;
      border-radius: 4px;
      font-size: 0.75rem;
      font-weight: 700;
      text-transform: uppercase;
      letter-spacing: 0.05em;
    }
    .grade-badge.high { background: var(--green); color: white; }
    .grade-badge.moderate { background: #3b82f6; color: white; }
    .grade-badge.low { background: var(--orange); color: white; }
    .grade-badge.very-low { background: var(--red); color: white; }

    /* Stats */
    .stats-grid {
      display: flex;
      gap: 0.75rem;
      margin: 1rem 0;
      flex-wrap: wrap;
      justify-content: center;
    }
    .stat-box {
      background: var(--navy);
      color: var(--cream);
      padding: 1rem 1.25rem;
      text-align: center;
      min-width: 120px;
      border-radius: 8px;
    }
    .stat-box.light { background: var(--light-cream); color: var(--navy); border: 1px solid var(--gold); }
    .stat-value {
      font-family: 'Cormorant Garamond', serif;
      font-size: clamp(1.3rem, 2.5vw, 2rem);
      font-weight: 700;
    }
    .stat-value.gold { color: var(--gold); }
    .stat-value.red { color: var(--red); }
    .stat-value.green { color: var(--green); }
    .stat-label { font-size: 0.75rem; opacity: 0.8; margin-top: 0.2rem; }

    /* Timeline */
    .timeline { display: flex; flex-direction: column; gap: 0.4rem; width: 100%; max-width: 650px; }
    .timeline-item {
      display: flex;
      align-items: center;
      gap: 0.75rem;
      padding: 0.6rem 0.75rem;
      background: rgba(255,255,255,0.05);
      border-radius: 6px;
      border-left: 4px solid var(--gold);
    }
    .timeline-days { font-weight: 700; font-size: 0.8rem; min-width: 70px; color: var(--gold); }
    .timeline-content { flex: 1; }
    .timeline-title { font-weight: 600; font-size: 0.9rem; }
    .timeline-desc { font-size: 0.75rem; opacity: 0.7; }

    /* Checklist */
    .checklist { display: flex; flex-direction: column; gap: 0.4rem; width: 100%; max-width: 650px; }
    .checklist-item {
      display: flex;
      align-items: flex-start;
      gap: 0.6rem;
      padding: 0.6rem 0.75rem;
      background: rgba(255,255,255,0.05);
      border-radius: 6px;
      border: 1px solid rgba(255,255,255,0.1);
    }
    .check-icon {
      width: 22px;
      height: 22px;
      background: var(--gold);
      color: var(--navy);
      border-radius: 4px;
      display: flex;
      align-items: center;
      justify-content: center;
      font-weight: 700;
      font-size: 0.75rem;
      flex-shrink: 0;
    }
    .checklist-text { font-size: 0.9rem; line-height: 1.4; }

    /* Lessons */
    .lesson-item { display: flex; align-items: flex-start; gap: 0.75rem; margin: 0.5rem 0; max-width: 700px; }
    .lesson-number {
      background: var(--gold);
      color: var(--navy);
      width: 28px;
      height: 28px;
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-weight: 700;
      font-size: 0.85rem;
      flex-shrink: 0;
    }
    .lesson-content h4 { font-size: 1rem; font-weight: 700; margin-bottom: 0.2rem; }
    .lesson-content p { font-size: 0.85rem; opacity: 0.8; }

    /* ====== DECISION TREE ====== */
    .decision-tree {
      width: 100%;
      max-width: 700px;
      background: linear-gradient(135deg, rgba(124,58,237,0.15), rgba(30,39,97,0.25));
      border: 2px solid var(--purple);
      border-radius: 12px;
      padding: 1.5rem;
      margin: 0.75rem 0;
    }
    .decision-header {
      display: flex;
      align-items: center;
      gap: 0.75rem;
      margin-bottom: 1rem;
    }
    .decision-icon {
      width: 40px;
      height: 40px;
      background: var(--purple);
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 1.25rem;
    }
    .decision-title {
      font-family: 'Cormorant Garamond', serif;
      font-size: 1.2rem;
      font-weight: 700;
    }
    .decision-xp {
      margin-left: auto;
      background: rgba(212,175,55,0.2);
      padding: 0.25rem 0.75rem;
      border-radius: 12px;
      font-size: 0.75rem;
      color: var(--gold);
      font-weight: 600;
    }
    .decision-scenario {
      background: rgba(0,0,0,0.2);
      padding: 1rem;
      border-radius: 8px;
      margin-bottom: 1rem;
      font-size: 0.95rem;
      line-height: 1.6;
    }
    .decision-question {
      font-weight: 600;
      color: var(--gold);
      margin-bottom: 0.75rem;
      font-size: 1rem;
    }
    .decision-options { display: flex; flex-direction: column; gap: 0.5rem; }
    .decision-option {
      display: flex;
      align-items: flex-start;
      gap: 0.75rem;
      padding: 0.75rem 1rem;
      background: rgba(255,255,255,0.05);
      border: 2px solid rgba(255,255,255,0.15);
      border-radius: 8px;
      cursor: pointer;
      transition: all 0.2s;
    }
    .decision-option:hover { background: rgba(124,58,237,0.2); border-color: var(--purple); }
    .decision-option.selected { background: rgba(124,58,237,0.3); border-color: var(--purple); }
    .decision-option.correct { background: rgba(34,197,94,0.2); border-color: var(--green); }
    .decision-option.incorrect { background: rgba(239,68,68,0.15); border-color: var(--red); }
    .decision-option.disabled { pointer-events: none; opacity: 0.7; }
    .decision-option:focus-visible { outline: 3px solid var(--gold); outline-offset: 2px; }
    .option-letter {
      width: 24px;
      height: 24px;
      background: rgba(255,255,255,0.1);
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-weight: 700;
      font-size: 0.8rem;
      flex-shrink: 0;
    }
    .decision-option.correct .option-letter { background: var(--green); color: white; }
    .decision-option.incorrect .option-letter { background: var(--red); color: white; }
    .option-text { font-size: 0.9rem; }
    .decision-feedback {
      margin-top: 1rem;
      padding: 1rem;
      border-radius: 8px;
      display: none;
    }
    .decision-feedback.show { display: block; }
    .decision-feedback.correct { background: rgba(34,197,94,0.2); border: 1px solid var(--green); }
    .decision-feedback.incorrect { background: rgba(239,68,68,0.15); border: 1px solid var(--red); }
    .feedback-title { font-weight: 700; margin-bottom: 0.5rem; display: flex; align-items: center; gap: 0.5rem; }
    .feedback-text { font-size: 0.9rem; line-height: 1.5; }

    /* ====== QUIZ ====== */
    .quiz-container { width: 100%; max-width: 650px; }
    .quiz-question {
      font-family: 'Cormorant Garamond', serif;
      font-size: 1.2rem;
      margin-bottom: 1.25rem;
      text-align: center;
    }
    .quiz-options { display: flex; flex-direction: column; gap: 0.5rem; }
    .quiz-option {
      padding: 0.75rem 1rem;
      background: rgba(255,255,255,0.05);
      border: 2px solid rgba(255,255,255,0.2);
      border-radius: 8px;
      cursor: pointer;
      transition: all 0.2s;
      text-align: left;
      font-size: 0.9rem;
    }
    .quiz-option:hover { background: rgba(212,175,55,0.15); border-color: var(--gold); }
    .quiz-option.correct { background: rgba(34,197,94,0.2); border-color: var(--green); }
    .quiz-option.incorrect { background: rgba(239,68,68,0.15); border-color: var(--red); }
    .quiz-option.disabled { pointer-events: none; }
    .quiz-option:focus-visible { outline: 3px solid var(--gold); outline-offset: 2px; }
    .quiz-feedback {
      margin-top: 1rem;
      padding: 1rem;
      border-radius: 8px;
      display: none;
      font-size: 0.9rem;
    }
    .quiz-feedback.show { display: block; }
    .quiz-feedback.correct { background: rgba(34,197,94,0.2); border: 1px solid var(--green); }
    .quiz-feedback.incorrect { background: rgba(239,68,68,0.15); border: 1px solid var(--red); }

    /* Learning Objectives */
    .objectives-box {
      background: linear-gradient(135deg, rgba(59,130,246,0.15), rgba(30,39,97,0.25));
      border: 2px solid #3b82f6;
      border-radius: 12px;
      padding: 1.25rem;
      margin: 0.75rem 0;
      max-width: 700px;
      width: 100%;
    }
    .objectives-header {
      display: flex;
      align-items: center;
      gap: 0.75rem;
      margin-bottom: 0.75rem;
    }
    .objectives-icon {
      width: 36px;
      height: 36px;
      background: #3b82f6;
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 1.1rem;
    }
    .objectives-title {
      font-family: 'Cormorant Garamond', serif;
      font-size: 1.1rem;
      font-weight: 700;
      color: #60a5fa;
    }
    .objectives-list { list-style: none; padding: 0; }
    .objectives-list li {
      display: flex;
      align-items: flex-start;
      gap: 0.5rem;
      padding: 0.4rem 0;
      font-size: 0.9rem;
    }
    .objectives-list li::before { content: '‚óã'; color: #3b82f6; font-weight: bold; }

    /* Animation */
    .slide.active .animate { animation: fadeUp 0.5s ease-out forwards; }
    .slide.active .animate.delay-1 { animation-delay: 0.1s; }
    .slide.active .animate.delay-2 { animation-delay: 0.2s; }
    .slide.active .animate.delay-3 { animation-delay: 0.3s; }
    @keyframes fadeUp {
      from { opacity: 0; transform: translateY(15px); }
      to { opacity: 1; transform: translateY(0); }
    }
    .animate { opacity: 0; }

    /* XP Popup */
    .xp-popup {
      position: fixed;
      top: 50%;
      left: 50%;
      transform: translate(-50%, -50%) scale(0);
      background: linear-gradient(135deg, var(--gold), #f0c040);
      color: var(--navy);
      padding: 1.5rem 2.5rem;
      border-radius: 12px;
      font-family: 'Cormorant Garamond', serif;
      font-size: 2rem;
      font-weight: 700;
      z-index: 1000;
      box-shadow: 0 10px 40px rgba(0,0,0,0.5);
      transition: transform 0.3s ease;
    }
    .xp-popup.show { transform: translate(-50%, -50%) scale(1); }
    .xp-popup .xp-amount { font-size: 3rem; display: block; }

    /* Badge Earned Modal */
    .badge-modal {
      position: fixed;
      top: 0; left: 0; right: 0; bottom: 0;
      background: rgba(0,0,0,0.85);
      display: none;
      justify-content: center;
      align-items: center;
      z-index: 1001;
    }
    .badge-modal.show { display: flex; }
    .badge-modal-content {
      background: linear-gradient(135deg, var(--deep-navy), #0a0f1a);
      border: 2px solid var(--gold);
      border-radius: 16px;
      padding: 2rem;
      text-align: center;
      max-width: 350px;
    }
    .badge-modal-icon { font-size: 4rem; margin-bottom: 1rem; }
    .badge-modal-title {
      font-family: 'Cormorant Garamond', serif;
      font-size: 1.5rem;
      color: var(--gold);
      margin-bottom: 0.5rem;
    }
    .badge-modal-desc { font-size: 0.9rem; opacity: 0.8; margin-bottom: 1rem; }
    .badge-modal-close {
      padding: 0.5rem 1.5rem;
      background: var(--gold);
      color: var(--navy);
      border: none;
      border-radius: 6px;
      font-weight: 600;
      cursor: pointer;
    }

    /* Confetti */
    .confetti-container {
      position: fixed;
      top: 0; left: 0;
      width: 100%; height: 100%;
      pointer-events: none;
      z-index: 999;
      overflow: hidden;
    }
    .confetti {
      position: absolute;
      width: 10px; height: 10px;
      opacity: 0;
      animation: confetti-fall 3s ease-out forwards;
    }
    @keyframes confetti-fall {
      0% { transform: translateY(-100px) rotate(0deg); opacity: 1; }
      100% { transform: translateY(100vh) rotate(720deg); opacity: 0; }
    }
    @media (prefers-reduced-motion: reduce) {
      .confetti { animation: none; display: none; }
      .xp-popup { transition: none; }
      .slide { transition: none; }
    }

    /* Nav */
    .slide-nav {
      position: absolute;
      bottom: 0; left: 0; right: 0;
      display: flex;
      justify-content: space-between;
      align-items: flex-end;
      padding: 0.75rem 1rem 1.25rem;
      z-index: 100;
      pointer-events: none;
    }
    .nav-btn {
      background: rgba(0,0,0,0.5);
      border: 1px solid rgba(255,255,255,0.2);
      color: white;
      font-size: 1.1rem;
      cursor: pointer;
      opacity: 0.6;
      transition: all 0.2s;
      padding: 0.4rem 0.6rem;
      border-radius: 6px;
      pointer-events: auto;
    }
    .nav-btn:hover { opacity: 1; background: rgba(0,0,0,0.7); border-color: var(--gold); }
    .nav-btn:disabled { opacity: 0.2; cursor: not-allowed; }
    .nav-btn:focus-visible { outline: 3px solid var(--gold); outline-offset: 2px; }
    .nav-center { display: flex; flex-direction: column; align-items: center; gap: 0.2rem; pointer-events: auto; }
    .slide-counter { font-size: 0.7rem; opacity: 0.5; }
    .progress-dots { display: flex; gap: 3px; flex-wrap: wrap; max-width: 220px; justify-content: center; }
    .progress-dot {
      width: 44px;
      height: 44px;
      display: flex;
      align-items: center;
      justify-content: center;
      cursor: pointer;
      background: none;
      border: none;
      padding: 0;
    }
    .progress-dot::after {
      content: '';
      width: 12px;
      height: 12px;
      border-radius: 50%;
      background: var(--text-muted, rgba(255,255,255,0.25));
      transition: all 0.2s ease;
    }
    .progress-dot.active::after,
    .progress-dot.completed::after {
      background: var(--gold);
      width: 14px;
      height: 14px;
    }

    /* Mobile */
    @media (max-width: 768px) {
      .sidebar {
        position: fixed;
        left: -300px;
        top: 0;
        bottom: 0;
        z-index: 1000;
        transition: left 0.3s ease;
      }
      .sidebar.open { left: 0; }
      .sidebar-toggle {
        display: flex;
        position: fixed;
        top: 10px;
        left: 10px;
        z-index: 1001;
        width: 40px;
        height: 40px;
        background: var(--gold);
        color: var(--navy);
        border: none;
        border-radius: 8px;
        align-items: center;
        justify-content: center;
        font-size: 1.2rem;
        cursor: pointer;
      }
      .sidebar-overlay {
        display: none;
        position: fixed;
        top: 0; left: 0; right: 0; bottom: 0;
        background: rgba(0,0,0,0.5);
        z-index: 999;
      }
      .sidebar-overlay.show { display: block; }
    }
    @media (min-width: 769px) {
      .sidebar-toggle { display: none; }
      .sidebar-overlay { display: none !important; }
    }

    /* Combo Counter */
    .combo-display {
      position: fixed;
      top: 80px;
      right: 20px;
      background: linear-gradient(135deg, var(--orange), #ef4444);
      color: white;
      padding: 0.5rem 1rem;
      border-radius: 20px;
      font-weight: 700;
      font-size: 0.9rem;
      z-index: 500;
      transform: scale(0);
      transition: transform 0.3s ease;
      box-shadow: 0 4px 15px rgba(239,68,68,0.4);
    }
    .combo-display.show { transform: scale(1); }
  </style>
</head>
<body>
<a class="skip-link" href="#main-content">Skip to main content</a>
<div class="course-container">
<!-- Sidebar -->
<nav aria-label="Navega√ß√£o do curso" class="sidebar" role="navigation">
<div class="sidebar-header">
<a href="index.html" onmouseout="this.style.color='rgba(212,175,55,0.7)'" onmouseover="this.style.color='#D4AF37'" style="display:block;font-size:0.7rem;color:rgba(212,175,55,0.7);text-decoration:none;margin-bottom:0.5rem;">‚Üê Course Library</a>
<h1>GRADE Mastery</h1>
<p>A arte de julgar evid√™ncias</p>
</div>
<div class="stats-panel">
<div class="level-display">
<div class="level-badge" id="levelIcon">üìä</div>
<div class="level-info">
<div class="level-title" id="levelTitle">Novice Appraiser</div>
<div class="level-subtitle">Level <span id="levelNum">1</span></div>
</div>
</div>
<div class="xp-bar"><div class="xp-fill" id="xpFill" style="width: 0%"></div></div>
<div class="xp-text"><span id="xpCurrent">0</span> / <span id="xpNeeded">100</span> XP</div>
<div class="quick-stats">
<div class="quick-stat">
<div class="quick-stat-value" id="correctCount">0</div>
<div class="quick-stat-label">Correct</div>
</div>
<div class="quick-stat">
<div class="quick-stat-value" id="decisionCount">0</div>
<div class="quick-stat-label">Decisions</div>
</div>
<div class="quick-stat">
<div class="quick-stat-value" id="gradesCount">0</div>
<div class="quick-stat-label">Graded</div>
</div>
</div>
</div>
<div class="course-progress">
<div class="course-progress-label">
<span>Course Progress</span>
<span id="courseProgressPct">0%</span>
</div>
<div class="course-progress-bar">
<div class="course-progress-fill" id="courseProgressFill" style="width: 0%"></div>
</div>
</div>
<div class="module-list" id="moduleList"></div>
<div class="badges-panel">
<div class="badges-title">Achievements</div>
<div class="badges-grid" id="badgesGrid"></div>
</div>
</nav>
<!-- Main Content -->
<main class="main-content" id="main-content">
<header class="content-header">
<div class="breadcrumb">GRADE Mastery / <span id="currentModule">Module 1</span></div>
<div class="header-actions">
<div class="streak-display" id="streakDisplay">
<span class="streak-flame">üî•</span>
<span class="streak-count" id="streakCount">0</span>
<span>day streak</span>
</div>
<button class="btn" onclick="resetProgress()">Reset</button>
</div>
</header>
<div class="content-body">
<div class="slides-container" id="slidesContainer"></div>
</div>
</main>
</div>
<!-- XP Popup -->
<div aria-atomic="true" aria-live="polite" class="xp-popup" id="xpPopup" role="status">
<span class="xp-amount" id="xpAmount">+25</span>
    XP
  </div>
<!-- Badge Modal -->
<div aria-labelledby="badgeModalTitle" aria-modal="true" class="badge-modal" id="badgeModal" role="dialog">
<div class="badge-modal-content">
<div class="badge-modal-icon" id="badgeModalIcon">üèÜ</div>
<div class="badge-modal-title" id="badgeModalTitle">Badge Earned!</div>
<div class="badge-modal-desc" id="badgeModalDesc">Voc√™ desbloqueou uma nova conquista</div>
<button class="badge-modal-close" onclick="closeBadgeModal()">Awesome!</button>
</div>
</div>
<!-- Confetti Container -->
<div class="confetti-container" id="confettiContainer"></div>
<!-- Combo Counter -->
<div aria-live="polite" class="combo-display" id="comboDisplay" role="status">üî• <span id="comboCount">0</span>x Combo!</div>
<!-- Mobile Sidebar Toggle -->
<button aria-expanded="false" aria-label="Toggle menu" class="sidebar-toggle" onclick="toggleSidebar()">‚ò∞</button>
<div class="sidebar-overlay" id="sidebarOverlay" onclick="toggleSidebar()"></div>
<script>
// ===== GAMIFICATION STATE =====
const DEFAULT_STATE = {
  xp: 0,
  level: 1,
  streak: 0,
  lastActive: null,
  correctAnswers: 0,
  decisionsCompleted: 0,
  gradesAssigned: 0,
  badges: [],
  completedModules: [],
  answeredQuestions: {},
  consecutiveCorrect: 0
};

function safeGetStorage(key, fallback) {
  try {
    const item = localStorage.getItem(key);
    return item ? JSON.parse(item) : fallback;
  } catch (e) {
    return fallback;
  }
}

function safeSetStorage(key, value) {
  try {
    localStorage.setItem(key, JSON.stringify(value));
  } catch (e) {}
}

// Migration from old storage key to versioned key
(function migrateStorage() {
  try {
    const oldData = localStorage.getItem('gradeGame');
    if (oldData && !localStorage.getItem('gradeGame_v1')) {
      localStorage.setItem('gradeGame_v1', oldData);
      localStorage.removeItem('gradeGame');
    }
  } catch (e) {}
})();

let gameState = safeGetStorage('gradeGame_v1', DEFAULT_STATE);

const LEVELS = [
  { level: 1, title: "Novice Appraiser", icon: "üìä", xp: 0 },
  { level: 2, title: "Bias Spotter", icon: "üîç", xp: 100 },
  { level: 3, title: "Certainty Seeker", icon: "‚öñÔ∏è", xp: 250 },
  { level: 4, title: "Evidence Evaluator", icon: "üìã", xp: 450 },
  { level: 5, title: "GRADE Apprentice", icon: "üéì", xp: 700 },
  { level: 6, title: "Certainty Guardian", icon: "üõ°Ô∏è", xp: 1000 },
  { level: 7, title: "Evidence Master", icon: "üèÜ", xp: 1400 },
  { level: 8, title: "GRADE Sage", icon: "üëë", xp: 1900 }
];

const BADGES = [
  { id: "first_grade", icon: "üìä", name: "First Rating", desc: "Assign your first GRADE rating" },
  { id: "bias_hunter", icon: "üîç", name: "Bias Hunter", desc: "Conclua o m√≥dulo Risco de preconceito" },
  { id: "precision_master", icon: "üéØ", name: "Precision Master", desc: "Conclua o m√≥dulo Imprecis√£o" },
  { id: "consistency_king", icon: "üîó", name: "Consistency King", desc: "Conclua o m√≥dulo Inconsist√™ncia" },
  { id: "directness_detective", icon: "üé™", name: "Directness Detective", desc: "Conclua o m√≥dulo Indireto" },
  { id: "publication_sleuth", icon: "üì∞", name: "Publication Sleuth", desc: "Conclua o vi√©s de publica√ß√£o m√≥dulo" },
  { id: "upgrader", icon: "‚¨ÜÔ∏è", name: "The Upgrader", desc: "Learn all upgrading factors" },
  { id: "perfect_5", icon: "‚≠ê", name: "Five Star", desc: "Get 5 correct answers in a row" },
  { id: "decision_maker", icon: "‚öñÔ∏è", name: "Decision Maker", desc: "Concluir 15 √°rvores de decis√£o" },
  { id: "finisher", icon: "üèÅ", name: "Course Complete", desc: "Concluir o curso inteiro" },
  { id: "streak_3", icon: "üî•", name: "On Fire", desc: "Maintain a 3-day streak" },
  { id: "streak_7", icon: "üí´", name: "Weekly Warrior", desc: "Maintain a 7-day streak" },
  { id: "grade_master", icon: "üëë", name: "GRADE Master", desc: "Concluir a avalia√ß√£o final" }
];

// ===== MODULES DATA =====
const MODULES = [
  {
    id: 1, title: "Why Certainty Matters", subtitle: "When confidence kills", xp: 150,
    slides: [
      { type: "title", theme: "dark", content: { title: "Why Certainty Matters", subtitle: "When overconfidence in evidence kills patients" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Understand why evidence certainty determines patient outcomes",
          "Aprenda com as diretrizes que mataram porque a certeza foi mal avaliada",
          "Reconhecer a diferen√ßa entre 'evid√™ncia existe' e 'evid√™ncia √© confi√°vel'",
          "Understand what GRADE provides that traditional reviews don't"
        ],
        tip: "Este m√≥dulo mostra por que errar na certeza tem consequ√™ncias reais."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "A cat√°strofe do betabloqueador", title: "Guidelines Based on a Liar",
        text: "For two decades, clinical guidelines worldwide recommended <strong>beta-blockers before non-cardiac surgery</strong> to prevent heart attacks. The recommendation was rated 'strong'‚Äîhigh certainty of benefit. Millions of patients received the drugs before operations. The evidence came largely from one man: <strong>Don Poldermans</strong>, who contributed 15 studies showing dramatic benefits.",
        followup: "In 2011, Poldermans was found guilty of research misconduct. His data was fabricated. When his studies were removed from meta-analyses, the math reversed: beta-blockers didn't prevent heart attacks‚Äîthey caused them. Researchers calculated the cost: following guidelines based on this fraudulent 'high certainty' evidence may have <strong>killed 800,000 patients</strong> over a decade. The certainty rating was wrong. The patients paid with their lives."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚ö†Ô∏è", title: "Cen√°rio: A recomenda√ß√£o forte",
        xp: 25,
        scenario: "Um painel de diretrizes classifica as evid√™ncias como 'altas certeza\" e emite uma \"recomenda√ß√£o forte\" para um tratamento preventivo. Voc√™ percebe que 60% das evid√™ncias v√™m de um √∫nico grupo de pesquisa cujas descobertas nunca foram replicadas de forma independente.",
        question: "Que preocupa√ß√£o voc√™ deve levantar sobre a classifica√ß√£o de certeza?",
        options: [
          { letter: "A", text: "Nenhuma ‚Äî estudos revisados por pares s√£o confi√°veis", correct: false },
          { letter: "B", text: "A certeza deve ser rebaixada por risco de vi√©s e falta de replica√ß√£o", correct: true },
          { letter: "C", text: "Solicite mais estudos do mesmo grupo para confirmar", correct: false },
          { letter: "D", text: "A recomenda√ß√£o forte compensa qualquer incerteza", correct: false }
        ],
        feedback: {
          correct: "Correto! As descobertas n√£o replicadas de Poldermans foram classificadas como de ‚Äúalta certeza‚Äù, apesar de dependerem de uma fonte. O GRADE exige o rebaixamento quando as evid√™ncias dependem fortemente de fontes potencialmente tendenciosas que n√£o possuem confirma√ß√£o independente.",
          incorrect: "800.000 mortes resultaram da confian√ßa em evid√™ncias n√£o replicadas de uma √∫nica fonte. Alta certeza requer replica√ß√£o independente. A concentra√ß√£o em um grupo de pesquisa √© um risco cr√≠tico de vi√©s."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "A revers√£o hormonal", title: "Two Million Women Betrayed",
        text: "For forty years, doctors prescribed <strong>hormone replacement therapy (HRT)</strong> to prevent heart disease in menopausal women. The evidence seemed overwhelming: observational studies showed <strong>50% fewer heart attacks</strong>. Experts were certain. Guidelines were strong. Two million American women took HRT specifically for heart protection.",
        followup: "In 2002, the Women's Health Initiative RCT delivered a verdict that shattered decades of certainty. HRT didn't prevent heart disease‚Äîit <strong>increased heart attacks by 29%</strong>, strokes by 41%, and breast cancer by 26%. The observational evidence had been confounded: healthy women chose HRT, creating an illusion of benefit. The certainty had been based on the wrong type of evidence. Two million women had taken a drug that harmed them, prescribed by doctors who were certain they were helping."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìä", title: "Scenario: Observational vs. RCT",
        xp: 25,
        scenario: "Vinte grandes estudos observacionais mostram que um tratamento reduz as mortes cardiovasculares em 45%. Dois pequenos ECRs n√£o mostram nenhum efeito. Um painel de diretrizes deve avaliar a certeza da evid√™ncia de benef√≠cio.",
        question: "What certainty rating is appropriate?",
        options: [
          { letter: "A", text: "Alto ‚Äî 20 estudos superam 2 estudos", correct: false },
          { letter: "B", text: "Moderate‚Äîmixed evidence requires caution", correct: false },
          { letter: "C", text: "Low‚ÄîRCTs trump observational studies; confounding likely explains the discrepancy", correct: true },
          { letter: "D", text: "Very Low‚Äîno conclusion is possible", correct: false }
        ],
        feedback: {
          correct: "Correto! O desastre da HRT nos ensinou exatamente essa li√ß√£o. Estudos observacionais que mostraram 50% de benef√≠cios foram superados por ECRs que mostraram danos. Quando os ECR contradizem os dados observacionais, a confus√£o √© a explica√ß√£o prov√°vel. GRADE inicia os ensaios cl√≠nicos randomizados em n√≠vel alto, observacionais em n√≠vel baixo.",
          incorrect: "HRT observational studies showed 50% benefit; the RCT showed 29% harm. The discrepancy was confounding‚Äîhealthy women chose HRT. RCT evidence, even from smaller studies, provides higher certainty than observational evidence for causal questions."
        }
      }},
      { type: "stats", theme: "dark", content: {
        title: "O custo da certeza errada",
        stats: [
          { value: "800K", label: "Mortes por fraude de Poldermans" },
          { value: "2M", label: "Women harmed by HRT" },
          { value: "50K", label: "CAST drug deaths" },
          { value: "83K", label: "Avandia heart attacks" }
        ],
        caption: "Cada desastre envolvia diretrizes que eram 'certas' com base em avalia√ß√µes de evid√™ncias falhas."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "O Intensivo Desastre de glicose", title: "ACCORD: When Tight Control Killed",
        text: "Diabetes doctors were certain: if high blood sugar caused complications, then tighter glucose control must prevent them. The logic seemed irrefutable. Guidelines recommended <strong>aggressive targets</strong>. The ACCORD trial enrolled 10,251 patients to prove what everyone already 'knew'‚Äîintensive glucose control saves lives.",
        followup: "In February 2008, the trial was stopped early. Not for benefit‚Äî<strong>for harm</strong>. Intensive glucose control increased deaths by 22%. The certainty had been based on biological plausibility, not actual outcome data. The surrogate outcome (glucose levels) improved while the patient-important outcome (survival) worsened. 257 excess deaths occurred in the intensive group. The guidelines had been confident. The confidence was misplaced."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üéØ", title: "Cen√°rio: O tratamento l√≥gico",
        xp: 25,
        scenario: "Um tratamento melhora drasticamente um biomarcador (valor de laborat√≥rio) que √© conhecido por causar doen√ßas. Nenhum ensaio mediu ainda os resultados cl√≠nicos reais, como morte ou hospitaliza√ß√£o. Um colega argumenta que a certeza do benef√≠cio √© 'alta' porque o mecanismo √© bem compreendido.",
        question: "What certainty rating should apply?",
        options: [
          { letter: "A", text: "High‚Äîclear mechanism implies clear benefit", correct: false },
          { letter: "B", text: "Moderate‚Äîmechanism is supportive but not definitive", correct: false },
          { letter: "C", text: "Low or Very Low‚Äîsurrogate outcomes don't guarantee patient-important benefits", correct: true },
          { letter: "D", text: "N√£o √© poss√≠vel avaliar at√© que os testes sejam conclu√≠dos", correct: false }
        ],
        feedback: {
          correct: "Correto! ACCORD, CAST e in√∫meros outros desastres seguiram a fal√°cia do ‚Äúmecanismo l√≥gico‚Äù. Melhorar os substitutos pode piorar os resultados. O GRADE exige rebaixamento para indiretividade quando apenas resultados substitutos s√£o medidos.",
          incorrect: "A terapia intensiva ACCORD melhorou a glicose perfeitamente enquanto matava os pacientes. Os medicamentos CAST corrigiram ECGs enquanto triplicavam as mortes. A plausibilidade biol√≥gica n√£o √© evid√™ncia cl√≠nica. Resultados importantes para o paciente s√£o necess√°rios para alta certeza."
        }
      }},
      { type: "concept", theme: "dark", content: {
        title: "What GRADE Provides",
        subtitle: "Uma estrutura sistem√°tica para certeza",
        text: "GRADE (Grading of Recommendations Assessment, Development and Evaluation) fornece um m√©todo estruturado e transparente para avaliar quanta confian√ßa devemos depositar nas evid√™ncias. Ela separa ‚Äúa evid√™ncia existe‚Äù de ‚Äúa evid√™ncia √© confi√°vel‚Äù.",
        highlight: "GRADE pergunta: 'Qu√£o confiantes estamos de que o efeito verdadeiro est√° pr√≥ximo do efeito estimado?'"
      }},
      { type: "story", theme: "dark", content: {
        label: "A revela√ß√£o da artroscopia", title: "A Billion-Dollar Placebo",
        text: "Knee arthroscopy for osteoarthritis was one of the most common orthopedic procedures in the world. <strong>700,000 Americans</strong> underwent it annually at a cost of $3 billion. Surgeons were certain it worked‚Äîthey saw patients improve. Insurance covered it. Guidelines recommended it.",
        followup: "Then came the sham surgery trials. Patients were randomized to real arthroscopy or fake surgery (incisions but no actual procedure). The result: <strong>no difference</strong>. Patients improved equally whether they received real surgery or placebo. Decades of certainty, billions of dollars, millions of surgeries‚Äîall based on the placebo effect that surgeons couldn't see. The certainty had been based on uncontrolled observations. Controlled trials revealed the truth."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üî¨", title: "Cen√°rio: O Cirurgi√£o Experiente",
        xp: 25,
        scenario: "Uma cirurgi√£ s√™nior argumenta que um procedimento ‚Äúdefinitivamente funciona‚Äù porque ela o realizou 2.000 vezes e ‚Äúviu pacientes melhorarem‚Äù. N√£o existem ensaios randomizados. Ela deseja que a diretriz classifique a certeza como ‚Äúmoderada‚Äù com base na experi√™ncia cl√≠nica.",
        question: "What certainty rating is appropriate?",
        options: [
          { letter: "A", text: "Moderate‚Äî2,000 cases is substantial experience", correct: false },
          { letter: "B", text: "Low‚Äîuncontrolled observations can't distinguish treatment effect from placebo", correct: true },
          { letter: "C", text: "Alta experi√™ncia especializada √© a forma mais elevada de evid√™ncia", correct: false },
          { letter: "D", text: "Muito baixo ‚Äì anedotas n√£o s√£o evid√™ncias", correct: false }
        ],
        feedback: {
          correct: "Correto! Os cirurgi√µes de artroscopia do joelho ‚Äúviram‚Äù pacientes melhorarem durante d√©cadas ‚Äì ent√£o ensaios de cirurgia simulada mostraram que era placebo. A experi√™ncia dos especialistas n√£o consegue detectar efeitos placebo. GRADE classifica as observa√ß√µes n√£o controladas como de certeza muito baixa.",
          incorrect: "Os cirurgi√µes realizaram 700.000 artroscopias anualmente, ‚Äúobservando‚Äù benef√≠cios ‚Äì isso foi inteiramente placebo. A experi√™ncia cl√≠nica, por mais extensa que seja, n√£o consegue distinguir os efeitos do tratamento da melhoria natural ou do placebo. Os ECR s√£o essenciais."
        }
      }},
      { type: "refrain", theme: "black", content: { text: "A certeza n√£o √© sobre quanta evid√™ncia existe. √â sobre o quanto devemos confiar nisso." }},
      { type: "quiz", theme: "dark", content: {
        question: "Por que os estudos observacionais de TRH enganaram os m√©dicos durante 40 anos?",
        options: [
          { text: "Os estudos foram fabricados", correct: false },
          { text: "Healthy women were more likely to choose HRT, creating confounding", correct: true },
          { text: "The RCTs used different doses", correct: false },
          { text: "Heart disease definitions changed over time", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Exatamente. A confus√£o por indica√ß√£o ‚Äì mulheres saud√°veis ‚Äã‚Äãescolheram a TRH ‚Äì criou uma ilus√£o de benef√≠cio. √â por isso que o GRADE classifica os estudos observacionais abaixo dos ECRs para quest√µes causais.",
          incorrect: "Os estudos eram reais, mas confusos. As mulheres saud√°veis ‚Äã‚Äãeram mais propensas a tomar TRH, fazendo com que parecesse ben√©fico. Os ECRs eliminam essa confus√£o aleatoriamente, revelando o verdadeiro efeito."
        }
      }}
    ]
  },
  {
    id: 2, title: "A Estrutura GRADE", subtitle: "Do alto ao muito baixo", xp: 120,
    slides: [
      { type: "title", theme: "dark", content: { title: "A Estrutura GRADE", subtitle: "Four levels of certainty, five reasons to doubt" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Aprenda os quatro n√≠veis de certeza GRADE e o que eles significam",
          "Understand starting points: RCTs vs observational studies",
          "Conhe√ßa os cinco dom√≠nios para rebaixar a certeza",
          "Conhe√ßa os tr√™s fatores para atualizar a evid√™ncia observacional"
        ],
        tip: "Este m√≥dulo fornece a estrutura que voc√™ aplicar√° ao longo do curso."
      }},
      { type: "stats", theme: "dark", content: {
        title: "Os quatro n√≠veis de certeza",
        stats: [
          { value: "‚äï‚äï‚äï‚äï", label: "HIGH" },
          { value: "‚äï‚äï‚äï‚óã", label: "MODERATE" },
          { value: "‚äï‚äï‚óã‚óã", label: "LOW" },
          { value: "‚äï‚óã‚óã‚óã", label: "VERY LOW" }
        ],
        caption: "Cada n√≠vel informa aos tomadores de decis√£o quanta confian√ßa deve ser depositada nas evid√™ncias."
      }},
      { type: "concept", theme: "dark", content: {
        title: "What Each Level Means",
        subtitle: "Practical interpretation",
        checkpoints: [
          { day: "HIGH", event: "Muito confiante de que o verdadeiro efeito est√° pr√≥ximo da estimativa" },
          { day: "MODERATE", event: "Moderately confident; true effect likely close but may differ" },
          { day: "LOW", event: "Limited confidence; true effect may be substantially different" },
          { day: "VERY LOW", event: "Very little confidence; true effect likely substantially different" }
        ]
      }},
      { type: "story", theme: "dark", content: {
        label: "O Princ√≠pio do Ponto de Partida", title: "Why RCTs Begin Higher",
        text: "In 1747, James Lind conducted what many consider the first controlled trial. Twelve sailors with scurvy were divided into six pairs, each receiving a different treatment. <strong>Only the two who received citrus fruits recovered.</strong> This simple comparison‚Äîtreated vs. untreated under similar conditions‚Äîrevealed truth that centuries of observation had missed.",
        followup: "Randomization is the great equalizer. It balances known and unknown confounders between groups. When patients are randomized, differences in outcomes can be attributed to the treatment, not to differences between patients. This is why GRADE starts RCT evidence at <strong>HIGH</strong> certainty and observational evidence at <strong>LOW</strong>‚Äîthe study design itself determines how much confounding might distort results."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üé≤", title: "Cen√°rio: o ponto de partida",
        xp: 25,
        scenario: "You're rating evidence for a new drug. You have three RCTs (total n=1,200) and five cohort studies (total n=45,000). A colleague argues the cohort studies should start at the same certainty level because they have more patients.",
        question: "Qual √© o ponto de partida correto para cada tipo de evid√™ncia?",
        options: [
          { letter: "A", text: "Both start at HIGH‚Äîsample size determines certainty", correct: false },
          { letter: "B", text: "RCTs start HIGH, cohorts start LOW‚Äîdesign determines starting point", correct: true },
          { letter: "C", text: "Cohorts start MODERATE because of large sample size", correct: false },
          { letter: "D", text: "Ambos come√ßam em MODERADO e ajustam a partir da√≠", correct: false }
        ],
        feedback: {
          correct: "Correto! Os pontos de partida do GRADE s√£o baseados no desenho do estudo, n√£o no tamanho da amostra. Os ECRs come√ßam em ALTO porque a randomiza√ß√£o controla a confus√£o. Os estudos observacionais come√ßam BAIXO porque a confus√£o n√£o pode ser eliminada, independentemente do tamanho.",
          incorrect: "Sample size affects precision, not confounding. The HRT cohort studies had millions of patients but were still wrong because of confounding. RCTs start HIGH; observational studies start LOW."
        }
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Cinco dom√≠nios para downgrade",
        items: [
          "Risco de vi√©s ‚Äî Os estudos apresentam alto risco de vi√©s?",
          "Inconsist√™ncia ‚Äî Os resultados variam inexplicavelmente entre os estudos?",
          "Indiretividade ‚Äî As evid√™ncias abordam diretamente a nossa quest√£o?",
          "Imprecision ‚Äî Is the effect estimate precise enough?",
          "Vi√©s de publica√ß√£o ‚Äî Faltam estudos na base de evid√™ncias?"
        ]
      }},
      { type: "story", theme: "red-bg", content: {
        label: "A Saga Tamiflu", title: "When All Five Domains Failed",
        text: "In 2009, governments stockpiled Tamiflu for pandemic flu. The UK spent <strong>¬£473 million</strong>. The evidence looked solid: published trials showed reduced complications. But Cochrane reviewers noticed problems in every GRADE domain.",
        followup: "<strong>Risk of bias:</strong> Trials were industry-funded with unclear methods. <strong>Inconsistency:</strong> Results varied between published and unpublished studies. <strong>Indirectness:</strong> 'Complications' were poorly defined. <strong>Imprecision:</strong> Confidence intervals were wide. <strong>Publication bias:</strong> 60% of patient data was never published. When Roche finally released the raw data after five years, the truth emerged: Tamiflu reduced symptom duration by less than a day and had no proven effect on hospitalizations or complications. Half a billion pounds spent on evidence that should have been rated VERY LOW."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìâ", title: "Cen√°rio: O problema de v√°rios dom√≠nios",
        xp: 25,
        scenario: "You're rating evidence from 5 RCTs. You find: unclear allocation concealment (risk of bias), I¬≤ = 75% with no explanation (inconsistency), and half the trials never published (publication bias). The trials themselves are precise and direct.",
        question: "Quantos n√≠veis voc√™ deve rebaixar de ALTO?",
        options: [
          { letter: "A", text: "One level‚Äîmultiple minor concerns equal one downgrade", correct: false },
          { letter: "B", text: "Two levels‚Äîserious concerns in two domains", correct: false },
          { letter: "C", text: "Three levels‚Äîserious concerns in three domains (to VERY LOW)", correct: true },
          { letter: "D", text: "Cannot downgrade RCTs‚Äîthey're always HIGH", correct: false }
        ],
        feedback: {
          correct: "Correct! Serious concerns in each domain typically warrant one downgrade each. Risk of bias (‚àí1), inconsistency (‚àí1), and publication bias (‚àí1) would take HIGH to VERY LOW. Multiple domains can compound.",
          incorrect: "Each domain with serious concerns typically warrants one downgrade. Three serious domain concerns = three downgrades. HIGH ‚àí 3 = VERY LOW. GRADE is cumulative."
        }
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Three Factors for Upgrading (Observational Only)",
        items: [
          "Large Effect ‚Äî Very large magnitude of effect (RR > 2 or < 0.5)",
          "Dose-Response ‚Äî Clear gradient between exposure and outcome",
          "Confounding ‚Äî All plausible confounding would reduce the effect"
        ]
      }},
      { type: "story", theme: "green-bg", content: {
        label: "A evid√™ncia de fumar", title: "When Observation Earned Certainty",
        text: "In the 1950s, Richard Doll and Austin Bradford Hill published observational studies linking cigarettes to lung cancer. No RCTs existed‚Äîyou cannot randomize people to smoke. Yet the evidence became <strong>HIGH certainty</strong>. Why?",
        followup: "Every upgrading criterion was met. <strong>Large effect:</strong> Smokers had 10-30x higher lung cancer rates‚Äîan effect size that confounding alone cannot explain. <strong>Dose-response:</strong> More cigarettes = more cancer in a clear gradient. <strong>Confounding direction:</strong> Any unmeasured confounder that caused both smoking and cancer would have to be implausibly powerful to explain the effect. When observational evidence meets all three upgrading criteria, it can achieve certainty that rivals RCTs."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚¨ÜÔ∏è", title: "Cen√°rio: a quest√£o da atualiza√ß√£o",
        xp: 25,
        scenario: "An observational study shows a treatment increases survival with RR = 1.3 (30% relative increase). The association is statistically significant with narrow confidence intervals. The authors argue this should be upgraded from LOW to MODERATE.",
        question: "Essa evid√™ncia deveria ser atualizada?",
        options: [
          { letter: "A", text: "Yes‚Äîstatistical significance warrants upgrading", correct: false },
          { letter: "B", text: "Yes‚Äînarrow confidence intervals warrant upgrading", correct: false },
          { letter: "C", text: "No‚ÄîRR 1.3 is not large enough; confounding could easily explain it", correct: true },
          { letter: "D", text: "No‚Äîobservational evidence can never be upgraded", correct: false }
        ],
        feedback: {
          correct: "Correct! RR 1.3 is well within the range that confounding can produce. Large effect upgrading typically requires RR > 2 or < 0.5‚Äîeffects so large that confounding alone is an implausible explanation. Statistical significance and precision are not upgrading criteria.",
          incorrect: "A 30% relative increase (RR 1.3) can easily result from modest confounding. The HRT studies showed RR 0.5 for heart protection‚Äîentirely due to confounding. Large effect upgrading requires effects that confounding cannot plausibly explain (typically RR > 2 or < 0.5)."
        }
      }},
      { type: "concept", theme: "dark", content: {
        title: "O Mnem√¥nico GRADE: RIIPP",
        subtitle: "Lembre-se dos 5 dom√≠nios em downgrade",
        text: "<strong style='color:var(--gold);font-size:1.5rem'>R</strong>isk of bias ‚Äî Can we trust the studies?<br><br><strong style='color:var(--gold);font-size:1.5rem'>I</strong>nconsistency ‚Äî Do studies agree?<br><br><strong style='color:var(--gold);font-size:1.5rem'>I</strong>ndirectness ‚Äî Does evidence match our question?<br><br><strong style='color:var(--gold);font-size:1.5rem'>I</strong>mprecision ‚Äî Is the estimate precise?<br><br><strong style='color:var(--gold);font-size:1.5rem'>P</strong>ublication bias ‚Äî Is evidence missing?",
        highlight: "RIIPP ‚Äî Lembre-se: 'As evid√™ncias RCT podem separar o RIIPP se esses dom√≠nios apresentarem problemas s√©rios.'"
      }},
      { type: "quiz", theme: "dark", content: {
        question: "Why do observational studies start at LOW certainty in GRADE?",
        options: [
          { text: "They usually have smaller sample sizes", correct: false },
          { text: "They cannot control for unmeasured confounding", correct: true },
          { text: "They are more often industry-funded", correct: false },
          { text: "Eles demoram mais para serem conclu√≠dos", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Exatamente. A randomiza√ß√£o equilibra os fatores de confus√£o entre os grupos. Sem ele, as diferen√ßas nos resultados podem refletir diferen√ßas nos pacientes, e n√£o nos efeitos do tratamento. Os estudos de TRH com milh√µes de pacientes ainda estavam errados devido √† confus√£o.",
          incorrect: "A quest√£o √© a confus√£o, n√£o o tamanho da amostra. Os estudos observacionais n√£o conseguem equilibrar fatores de confus√£o desconhecidos da mesma forma que a randomiza√ß√£o. Essa limita√ß√£o fundamental determina o ponto de partida."
        }
      }}
    ]
  },
  {
    id: 3, title: "Risk of Bias", subtitle: "Quando os estudos mentem", xp: 180,
    slides: [
      { type: "title", theme: "purple-bg", content: { title: "Risk of Bias", subtitle: "O primeiro dom√≠nio: Podemos confiar nesses estudos?" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Identificar os principais dom√≠nios de vi√©s em ECRs e estudos observacionais",
          "Recognize how bias inflates or deflates treatment effects",
          "Apply risk of bias assessment to real examples",
          "Decide when to downgrade certainty for bias"
        ],
        tip: "Concluir todos os cen√°rios de decis√£o para ganhar o Bias Hunter crach√°!"
      }},
      { type: "story", theme: "red-bg", content: {
        label: "A Decep√ß√£o VIGOR", title: "When Merck Chose the Cutoff",
        text: "In 2000, Merck published the VIGOR trial comparing Vioxx to naproxen. The New England Journal of Medicine reported a 4-fold increase in heart attacks with Vioxx. But the published paper hid something: <strong>three additional heart attacks</strong> occurred in the Vioxx group after the data cutoff date. Merck scientists knew about them.",
        followup: "Those three heart attacks mattered. Including them would have changed the risk ratio from 'concerning' to 'alarming.' Instead, Merck's chosen cutoff date‚Äîa methodological decision made after seeing the data‚Äîobscured the true risk. The NEJM later published an 'expression of concern,' calling the paper 'inaccurate and incomplete.' By then, tens of thousands had suffered heart attacks from a drug whose danger had been hidden by selective reporting. The bias wasn't in the trial design‚Äîit was in how the data was analyzed and presented."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚úÇÔ∏è", title: "Cen√°rio: O Ponto de Corte M√≥vel",
        xp: 30,
        scenario: "Voc√™ est√° avaliando um estudo que mudou seu ponto de tempo de an√°lise principal ap√≥s o in√≠cio do estudo - de 12 meses para 6 meses. Os resultados de 6 meses favorecem o tratamento. Os autores dizem que a mudan√ßa foi feita por \"raz√µes administrativas\" n√£o relacionadas aos resultados.",
        question: "Como isso deve afetar sua avalia√ß√£o de risco de vi√©s?",
        options: [
          { letter: "A", text: "No concern‚Äîadministrative changes happen", correct: false },
          { letter: "B", text: "Alto risco de vi√©s para relat√≥rios seletivos ‚Äì altera√ß√µes de ponto de tempo ap√≥s a visualiza√ß√£o dos dados s√£o suspeitas", correct: true },
          { letter: "C", text: "Baixo risco se os dados de 12 meses tamb√©m forem relatado", correct: false },
          { letter: "D", text: "Unclear risk‚Äîwe cannot know their true motivation", correct: false }
        ],
        feedback: {
          correct: "Correto! Altera√ß√µes post-hoc nos planos de an√°lise representam um alto risco para relat√≥rios seletivos. O corte de dados do VIGOR foi uma ‚Äúdecis√£o metodol√≥gica‚Äù que escondeu tr√™s ataques card√≠acos. Quando os pontos de tempo mudam ap√≥s o ac√∫mulo de dados, presuma o pior.",
          incorrect: "A data limite 'metodol√≥gica' da Merck escondeu ataques card√≠acos fatais. As altera√ß√µes na an√°lise post-hoc ‚Äì especialmente quando os resultados favorecem o tratamento ‚Äì s√£o relat√≥rios seletivos cl√°ssicos. GRADE exige ceticismo sobre modifica√ß√µes post-hoc."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "O problema do r√≥tulo aberto", title: "When Knowing Changes Everything",
        text: "The ASCOT-LLA trial compared atorvastatin to placebo for cardiovascular prevention. The primary endpoint was non-fatal MI plus fatal CHD‚Äî<strong>objective outcomes</strong> that shouldn't depend on whether doctors knew which treatment patients received.",
        followup: "But doctors did know. The trial was stopped early when the Data Safety Monitoring Board saw benefit. The problem: some outcomes were adjudicated by committees who were <strong>not blinded</strong> to treatment assignment. Did knowing a patient was on statin affect how borderline MIs were classified? Studies comparing blinded vs. unblinded assessment show systematic differences. Open-label designs can inflate apparent benefits by 10-20% even for 'objective' outcomes. ASCOT-LLA was rated down for risk of bias despite being an RCT."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üëÅÔ∏è", title: "Cen√°rio: os avaliadores n√£o cegos",
        xp: 25,
        scenario: "Um RCT de uma interven√ß√£o cir√∫rgica relata uma redu√ß√£o de 30% em 'grandes eventos cardiovasculares'. O estudo foi necessariamente n√£o cego (os pacientes sabiam se seriam operados). Os avaliadores de resultados tamb√©m n√£o foram cegados. Os eventos foram julgados por um comit√™ que conhecia as atribui√ß√µes do tratamento.",
        question: "Qual √© o risco de vi√©s para vi√©s de detec√ß√£o?",
        options: [
          { letter: "A", text: "Low‚Äîcardiovascular events are objective", correct: false },
          { letter: "B", text: "High‚Äîunblinded assessment of cardiovascular events inflates effects", correct: true },
          { letter: "C", text: "N√£o est√° claro ‚Äî precisamos de mais informa√ß√µes sobre o comit√™", correct: false },
          { letter: "D", text: "Not applicable‚Äîsurgical trials cannot be blinded", correct: false }
        ],
        feedback: {
          correct: "Correct! Even 'objective' outcomes like MI involve judgment calls (borderline troponins, ECG interpretations). Studies show unblinded assessment inflates effects 10-20%. Outcome assessors should always be blinded when possible, regardless of intervention blinding.",
          incorrect: "Cardiovascular events require interpretation‚Äîborderline troponin elevations, ECG changes, symptom classification. Unblinded assessors systematically favor the intervention. Outcome assessment should be blinded even when intervention blinding is impossible."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "A viola√ß√£o do ITT", title: "Roche's Missing Patients",
        text: "In Tamiflu trials, Roche excluded patients from analysis after randomization. Some were excluded for 'protocol violations'‚Äîbut the violations often occurred <strong>after</strong> patients had taken the drug and experienced side effects. Patients who developed complications were retroactively deemed 'protocol violators' and removed.",
        followup: "Intention-to-treat (ITT) analysis exists precisely to prevent this. Once randomized, always analyzed‚Äîregardless of what happens afterward. Excluding patients after randomization destroys the balance that randomization created. Roche's selective exclusions removed patients who had adverse outcomes, making Tamiflu appear safer and more effective than it was. The Cochrane review downgraded certainty specifically for these ITT violations."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üö™", title: "Cen√°rio: a p√≥s-randomiza√ß√£o Exclus√µes",
        xp: 25,
        scenario: "A trial randomizes 500 patients per arm. The paper reports results for 420 vs. 380 patients, with 80 and 120 exclusions respectively. Reasons include: 'withdrew consent,' 'lost to follow-up,' and 'protocol deviation.' More patients were excluded from the control arm.",
        question: "What risk of bias concern does this raise?",
        options: [
          { letter: "A", text: "No concern‚Äîexclusions happen in every trial", correct: false },
          { letter: "B", text: "High risk of attrition bias‚Äîdifferential exclusions destroy randomization balance", correct: true },
          { letter: "C", text: "Low risk if reasons are documented", correct: false },
          { letter: "D", text: "Unclear‚Äîwe need to know why controls were excluded more", correct: false }
        ],
        feedback: {
          correct: "Correto! O atrito diferencial (120 vs. 80 exclus√µes) sugere que os grupos n√£o s√£o mais compar√°veis. Se os pacientes de controle que n√£o estavam melhorando tivessem maior probabilidade de desistir, os controles restantes pareceriam mais saud√°veis ‚Äã‚Äãdo que deveriam. Isso aumenta o benef√≠cio aparente do tratamento.",
          incorrect: "Exclus√µes diferenciais (120 vs. 80) quebram a randomiza√ß√£o. Os restantes grupos j√° n√£o est√£o equilibrados. Se os pacientes de controle mais doentes desistirem, o grupo de controle parecer√° artificialmente saud√°vel. GRADE exige rebaixamento para desgaste diferencial substancial."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "A lacuna de registro", title: "Os resultados que desapareceram",
        text: "A systematic review of trial registration found that <strong>31% of trials</strong> changed their primary outcome between registration and publication. The changes weren't random‚Äîthey systematically favored positive results. Outcomes that showed benefit were promoted to primary; outcomes showing no effect were demoted or disappeared.",
        followup: "Selective outcome reporting is invisible without registration comparison. A trial might register five outcomes, find benefit in one, and publish only that one as the 'primary' outcome. The reader sees a positive trial. The reality: 4 of 5 outcomes showed nothing. PROSPERO registration for systematic reviews and ClinicalTrials.gov for trials exist specifically to combat this. When assessing risk of bias, always compare published outcomes to registered protocols."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìã", title: "Scenario: The Primary Outcome Switch",
        xp: 25,
        scenario: "Voc√™ compara um estudo publicado ao seu registro. O registro lista a ‚Äúmorte cardiovascular‚Äù como prim√°ria. A publica√ß√£o lista o ‚Äúcomposto de morte cardiovascular, infarto do mioc√°rdio ou acidente vascular cerebral‚Äù como prim√°rio e relata-o como significativo. A morte cardiovascular sozinha √© enterrada em uma tabela e n√£o mostra nenhuma diferen√ßa significativa.",
        question: "What risk of bias rating is appropriate?",
        options: [
          { letter: "A", text: "Low‚Äîcomposite endpoints are clinically reasonable", correct: false },
          { letter: "B", text: "High‚Äîthis is outcome switching to achieve significance", correct: true },
          { letter: "C", text: "Unclear‚Äîthe authors may have had good reasons", correct: false },
          { letter: "D", text: "Baixo se o composto foi pr√©-especificado no protocolo", correct: false }
        ],
        feedback: {
          correct: "Correto! Mudar de um resultado restrito (morte CV) para um composto mais amplo (morte CV/IAM/AVC) depois de ver que o resultado restrito falhou √© uma mudan√ßa de resultado cl√°ssica. Os 31% dos ensaios que fazem isso aumentam sistematicamente os resultados positivos.",
          incorrect: "Trata-se de uma mudan√ßa de resultados ‚Äì o prim√°rio registado falhou, pelo que foi promovido um composto mais amplo. A signific√¢ncia composta pode ser inteiramente determinada pelos componentes menos importantes. Compare cada publica√ß√£o com seu registro."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "A Auditoria da Avandia", title: "38,000 Heart Attacks Exposed by One Cardiologist",
        text: "In 2007, Dr. Steven Nissen at the Cleveland Clinic did what regulators hadn't: he pooled all available rosiglitazone (Avandia) data. <strong>42 trials, 27,847 patients</strong>. The FDA had approved Avandia based on surrogate outcomes‚Äîit lowered blood sugar beautifully. But Nissen asked a different question: what about hearts?",
        followup: "His meta-analysis revealed the truth: Avandia increased heart attacks by <strong>43%</strong> (OR 1.43, 95% CI 1.03-1.98). GSK had conducted these trials. GSK had the data. But the data on cardiovascular events had been scattered across trials, buried in adverse event tables, never pooled. When Nissen pooled it, the pattern became undeniable. The FDA estimated <strong>83,000 excess heart attacks</strong> between 1999-2007. The bias wasn't in study conduct‚Äîit was in how results were analyzed and presented. Selective synthesis can be as dangerous as selective reporting."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìë", title: "Cen√°rio: Os dados de seguran√ßa dispersos",
        xp: 25,
        scenario: "A drug has been studied in 30 trials for various conditions. Each trial reports a few adverse cardiac events in supplementary tables, but no single trial was powered for cardiac outcomes. A meta-analysis combining cardiac events across all 30 trials shows RR 1.35 (95% CI 1.10-1.65) for heart attacks.",
        question: "How should this post-hoc safety signal affect certainty?",
        options: [
          { letter: "A", text: "Ignore it‚Äîtrials weren't designed for cardiac outcomes", correct: false },
          { letter: "B", text: "Leve isso a s√©rio - eventos adversos agrupados podem revelar sinais reais mesmo a partir de an√°lises post-hoc", correct: true },
          { letter: "C", text: "Dismiss it‚Äîmeta-analysis of adverse events is unreliable", correct: false },
          { letter: "D", text: "Wait for a dedicated cardiac outcome trial before acting", correct: false }
        ],
        feedback: {
          correct: "Correto! A an√°lise do Avandia de Nissen foi um agrupamento ‚Äúpost-hoc‚Äù de eventos adversos dispersos ‚Äì e revelou 83.000 ataques card√≠acos excessivos. Os sinais de seguran√ßa post-hoc da meta-an√°lise podem ser reais. A aus√™ncia de resultados card√≠acos pr√©-especificados n√£o significa que eventos card√≠acos n√£o ocorreram.",
          incorrect: "O caso Avandia provou que o agrupamento post-hoc de eventos adversos pode revelar danos genu√≠nos. Esperar por um julgamento dedicado enquanto 83.000 ataques card√≠acos se acumulavam teria sido injusto. Os sinais de seguran√ßa provenientes de meta-an√°lise de eventos adversos merecem s√©ria considera√ß√£o."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "A Decep√ß√£o ENHANCE", title: "When Merck Hid What They Found",
        text: "Em 2006, a Merck concluiu o ensaio ENHANCE de Vytorin (ezetimiba + sinvastatina) para aterosclerose. O estudo mediu a espessura da art√©ria car√≥tida ‚Äì um substituto para doen√ßas cardiovasculares. Os resultados deveriam ser divulgados no in√≠cio de 2007. A Merck anunciou um 'atraso' para 'an√°lises adicionais'.",
        followup: "The 'additional analyses' took <strong>two years</strong>. When finally released in 2008, ENHANCE showed <strong>no benefit</strong>‚ÄîVytorin didn't reduce artery thickness despite lowering LDL cholesterol. During those two years of concealment, Vytorin sales exceeded <strong>$5 billion</strong>. Congressional investigations revealed internal documents showing Merck knew the results were negative in 2006. The delay wasn't for analysis‚Äîit was for commercial protection. Publication delay is a form of selective reporting: timing becomes a bias tool."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚è∞", title: "Cen√°rio: O Atraso Suspeito",
        xp: 25,
        scenario: "Um ensaio altamente antecipado de um medicamento de grande sucesso deveria relatar resultados h√° 18 meses. A empresa cita ‚Äúan√°lises em andamento‚Äù e ‚Äúproblemas de qualidade dos dados‚Äù. Enquanto isso, a droga continua vendendo bilh√µes anualmente. Ensaios de concorrentes j√° foram relatados.",
        question: "O que voc√™ deve suspeitar sobre os resultados n√£o relatados?",
        options: [
          { letter: "A", text: "Nothing‚Äîdata quality takes time", correct: false },
          { letter: "B", text: "Likely negative or harmful‚Äîcompanies delay bad news, not good news", correct: true },
          { letter: "C", text: "Likely positive‚Äîthey're waiting for regulatory approval", correct: false },
          { letter: "D", text: "Cannot infer anything from publication timing", correct: false }
        ],
        feedback: {
          correct: "Correct! The ENHANCE delay taught us: companies don't delay good news for two years. Unexplained publication delays, especially for products still generating revenue, are strong evidence of unfavorable results. Consider delayed trials as potentially biased against the intervention.",
          incorrect: "O momento da publica√ß√£o √© informativo. As empresas aceleram a publica√ß√£o de resultados positivos (pre√ßo das a√ß√µes, marketing) e atrasam os negativos (vendas cont√≠nuas). Um atraso de 18 meses para um medicamento de grande sucesso sugere fortemente que os resultados n√£o apoiam o uso continuado."
        }
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Risk of Bias Domains (RCTs)",
        items: [
          "Random sequence generation ‚Äî Was randomization truly random?",
          "Allocation concealment ‚Äî Could anyone predict assignments?",
          "Blinding of participants/personnel ‚Äî Did they know treatment?",
          "Blinding of outcome assessment ‚Äî Did assessors know treatment?",
          "Dados de resultados incompletos ‚Äî O atrito foi equilibrado e explicado?",
          "Selective reporting ‚Äî Are registered outcomes all reported?",
          "Other bias ‚Äî Baseline imbalances, early stopping, etc."
        ]
      }},
      { type: "quiz", theme: "dark", content: {
        question: "Why does GRADE downgrade for open-label outcome assessment even when outcomes seem 'objective'?",
        options: [
          { text: "Open-label trials are always lower quality", correct: false },
          { text: "Even objective outcomes involve judgment calls affected by knowledge of treatment", correct: true },
          { text: "Regulations require blinded assessment", correct: false },
          { text: "√â uma conven√ß√£o conservadora, n√£o baseada em evid√™ncias", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Certo! IM lim√≠trofe, sintomas incertos de AVC, altera√ß√µes discut√≠veis no ECG ‚Äì tudo isso envolve interpreta√ß√£o. Estudos mostram que a avalia√ß√£o n√£o cega favorece sistematicamente o tratamento conhecido em 10-20%, mesmo para desfechos ‚Äúdif√≠ceis‚Äù.",
          incorrect: "Pesquisas mostram que a avalia√ß√£o n√£o cega aumenta os efeitos mesmo para resultados que parecem objetivos. Os casos lim√≠trofes s√£o interpretados em favor do efeito esperado. Isso √© vi√©s de detec√ß√£o."
        }
      }}
    ]
  },
  {
    id: 4, title: "Inconsistency", subtitle: "Quando os estudos discordam", xp: 160,
    slides: [
      { type: "title", theme: "orange-bg", content: { title: "Inconsistency", subtitle: "O segundo dom√≠nio: O que fazemos quando os estudos discordam?" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Entenda por que os resultados dos estudos variam e quando a varia√ß√£o √© preocupante",
          "Interprete as estat√≠sticas I¬≤ e tau¬≤ para heterogeneidade",
          "Distinguish explainable from unexplainable inconsistency",
          "Decide when to downgrade certainty for inconsistency"
        ],
        tip: "Real disagreement between studies tells us something important."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "A vitamina D Contradi√ß√£o", title: "Quando 200 estudos n√£o conseguiram concordar",
        text: "By 2019, over <strong>200 randomized trials</strong> had studied vitamin D supplementation. The results were chaos. Some showed vitamin D prevented cancer (RR 0.77). Others showed no effect (RR 1.02). Some showed harm (RR 1.15). Meta-analyses pooled them all and proclaimed 'statistically significant benefit.' But the I¬≤ was <strong>78%</strong>‚Äîmassive heterogeneity that the summary estimate concealed.",
        followup: "The largest trial, VITAL (25,871 participants), finally brought clarity. It showed <strong>no benefit</strong> for cancer or cardiovascular disease. The smaller positive studies had methodological problems: inadequate randomization, post-hoc analyses, selected populations. The pooled estimate had hidden a crucial truth: when studies wildly disagree, the average may represent no one's truth. GRADE requires downgrading for this kind of inconsistency, regardless of what the pooled estimate shows."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìä", title: "Cen√°rio: a meta-an√°lise heterog√™nea",
        xp: 25,
        scenario: "A meta-analysis of 15 trials shows pooled benefit (OR 0.75, p<0.001). However, I¬≤ = 82%, tau¬≤ is large, and the prediction interval crosses 1.0. Six trials show harm, nine show benefit. The authors conclude 'significant benefit with moderate heterogeneity.'",
        question: "How should inconsistency affect the certainty rating?",
        options: [
          { letter: "A", text: "No downgrade‚Äîthe pooled estimate is statistically significant", correct: false },
          { letter: "B", text: "Downgrade one level‚ÄîI¬≤ > 75% is substantial heterogeneity", correct: false },
          { letter: "C", text: "Downgrade one or two levels‚Äîprediction interval crossing 1.0 means future studies might show harm", correct: true },
          { letter: "D", text: "Cannot rate‚Äîinconsistent evidence is uninterpretable", correct: false }
        ],
        feedback: {
          correct: "Correct! The prediction interval is key. When it crosses the null, we're saying: 'If we did another study, it might show the opposite effect.' That's profound uncertainty. I¬≤ = 82% with a prediction interval crossing 1.0 warrants serious downgrading.",
          incorrect: "I¬≤ de 82% √© heterogeneidade severa, mas o intervalo de previs√£o √© mais informativo. Ultrapassar 1,0 significa que estudos futuros podem mostrar danos ‚Äì o ‚Äúbenef√≠cio‚Äù agrupado pode n√£o se aplicar ao pr√≥ximo paciente. A signific√¢ncia estat√≠stica da estimativa combinada n√£o resgata evid√™ncias inconsistentes."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "O Mist√©rio do AVC", title: "Aspirin's Vanishing Benefit",
        text: "In 1988, the ISIS-2 trial proved aspirin reduced death after heart attack by <strong>23%</strong>. The evidence was bulletproof‚Äî17,187 patients, clear benefit, minimal heterogeneity when pooled with similar trials. Aspirin became standard care.",
        followup: "But stroke prevention was different. Meta-analyses of aspirin for primary prevention showed <strong>wildly inconsistent results</strong>. Some trials showed 15% reduction in stroke. Others showed 10% increase. The I¬≤ exceeded 60%. The explanation emerged slowly: aspirin prevents <strong>ischemic</strong> stroke but causes <strong>hemorrhagic</strong> stroke. When trials measured 'all stroke,' results depended on the baseline mix of stroke types in each population. The inconsistency wasn't noise‚Äîit was biology. Understanding <em>why</em> studies differ changes interpretation entirely."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üîç", title: "Cen√°rio: A Inconsist√™ncia Explic√°vel",
        xp: 25,
        scenario: "A meta-analysis shows I¬≤ = 70%. However, subgroup analysis reveals: trials in high-risk patients show consistent benefit (I¬≤ = 15%, OR 0.60), while trials in low-risk patients show consistent null effects (I¬≤ = 20%, OR 1.02). The high I¬≤ is entirely explained by mixing these populations.",
        question: "Voc√™ deve fazer downgrade por inconsist√™ncia?",
        options: [
          { letter: "A", text: "Yes‚ÄîI¬≤ = 70% always requires downgrading", correct: false },
          { letter: "B", text: "No‚Äîinconsistency is fully explained by a pre-specified, biologically plausible subgroup", correct: true },
          { letter: "C", text: "Partially‚Äîdowngrade one level despite the explanation", correct: false },
          { letter: "D", text: "Report two separate certainty ratings for each subgroup", correct: false }
        ],
        feedback: {
          correct: "Correto! GRADE distingue a heterogeneidade inexplic√°vel (rebaixamento) da heterogeneidade totalmente explicada por efeitos cred√≠veis de subgrupos (sem rebaixamento por inconsist√™ncia). A explica√ß√£o deve ser pr√©-especificada e biologicamente plaus√≠vel - n√£o dragagem de dados post-hoc.",
          incorrect: "When heterogeneity is fully explained by a pre-specified, credible subgroup effect, the 'inconsistency' actually tells us something useful: treatment works differently in different populations. This informs clinical practice rather than undermining certainty."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "O Paradoxo da Albumina", title: "28 Trials, Zero Answers",
        text: "Should critically ill patients receive albumin for fluid resuscitation? By 1998, the Cochrane Injuries Group had pooled <strong>28 trials</strong>. Their conclusion: albumin <strong>increases mortality by 68%</strong> (RR 1.68). Headlines screamed. NHS considered banning albumin. The evidence seemed damning.",
        followup: "But look closer at those 28 trials. I¬≤ was <strong>0%</strong>‚Äîno heterogeneity. A different problem lurked: the trials were tiny (many with <50 patients), measured different populations (burns, trauma, surgery), and many were decades old. The <strong>SAFE trial</strong> (6,997 patients, 2004) finally answered the question: albumin was <strong>equivalent to saline</strong>‚Äîno benefit, no harm. The pooled estimate from 28 small, disparate trials had been an artifact of random variation in underpowered studies, not a real signal. Consistency (low I¬≤) doesn't guarantee truth."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚öñÔ∏è", title: "Cen√°rio: As evid√™ncias consistentes, mas preocupantes",
        xp: 25,
        scenario: "A meta-analysis pools 12 small trials (total n=400) with I¬≤ = 5%‚Äîvery low heterogeneity. The pooled effect is OR 0.50 (dramatic benefit), statistically significant. A colleague argues this deserves HIGH certainty because results are 'beautifully consistent.'",
        question: "What concern should you raise?",
        options: [
          { letter: "A", text: "None‚Äîlow I¬≤ means high certainty for inconsistency", correct: false },
          { letter: "B", text: "Low I¬≤ in small trials may reflect consistent bias, not consistent truth", correct: true },
          { letter: "C", text: "I¬≤ = 5% is too low and suggests publication bias", correct: false },
          { letter: "D", text: "The pooled estimate is too dramatic to be real", correct: false }
        ],
        feedback: {
          correct: "Correto! Ensaios pequenos com resultados dram√°ticos consistentes devem levantar suspeitas. Eles podem compartilhar os mesmos preconceitos (vi√©s de publica√ß√£o, m√©todos semelhantes e falhos). A meta-an√°lise da albumina teve I¬≤ pr√≥ximo de 0% em 28 ensaios ‚Äì mas o grande ensaio SAFE mostrou efeito nulo. Consist√™ncia em pequenos ensaios ‚â† verdade.",
          incorrect: "Low heterogeneity among small, potentially biased trials can be misleading. If all trials share similar biases (publication bias, poor methods), they'll show consistently biased results. The albumin case proves this: I¬≤ was low, but the effect was an artifact."
        }
      }},
      { type: "stats", theme: "dark", content: {
        title: "Understanding I¬≤ Thresholds",
        stats: [
          { value: "0-25%", label: "Low heterogeneity" },
          { value: "25-50%", label: "Moderate" },
          { value: "50-75%", label: "Substantial" },
          { value: ">75%", label: "Considerable" }
        ],
        caption: "Mas o I¬≤ por si s√≥ n√£o determina o rebaixamento ‚Äì o intervalo de previs√£o e o significado cl√≠nico s√£o mais importantes."
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Inconsistency Assessment Checklist",
        items: [
          "Calculate I¬≤ and tau¬≤ ‚Äî but don't stop there",
          "Examine prediction interval ‚Äî does it cross clinically important thresholds?",
          "Procure intervalos de confian√ßa sobrepostos entre estudos",
          "Check if heterogeneity can be explained by credible subgroups",
          "Consider if small trials are driving inconsistency (vs. large trial disagreement)"
        ]
      }},
      { type: "quiz", theme: "dark", content: {
        question: "Por que o intervalo de predi√ß√£o √© mais importante que I¬≤ para avalia√ß√£o de inconsist√™ncia GRADE?",
        options: [
          { text: "Prediction intervals are easier to calculate", correct: false },
          { text: "Prediction intervals tell us what effect a future study might show", correct: true },
          { text: "I¬≤ is only valid for large meta-analyses", correct: false },
          { text: "Prediction intervals account for publication bias", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Exactly. The prediction interval says: 'The next study from this distribution of effects will probably fall in this range.' If that range includes harm while the pooled estimate shows benefit, we're deeply uncertain about what will happen to the next patient.",
          incorrect: "The prediction interval captures uncertainty about what future studies (or the next patient) might experience. I¬≤ tells us whether heterogeneity exists; the prediction interval tells us whether it matters clinically."
        }
      }}
    ]
  },
  {
    id: 5, title: "Indirectness", subtitle: "Pergunta errada, resposta errada", xp: 170,
    slides: [
      { type: "title", theme: "purple-bg", content: { title: "Indirectness", subtitle: "O terceiro dom√≠nio: esta evid√™ncia responde √† nossa quest√£o real?" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Recognize four types of indirectness: population, intervention, comparator, outcome",
          "Understand why surrogate outcomes mislead",
          "Apply indirectness assessment to real scenarios",
          "Decide when evidence is too indirect to trust"
        ],
        tip: "A melhor evid√™ncia para a pergunta errada ainda √© a resposta errada."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "A Cat√°strofe STARRING", title: "50.000 mortos devido a um tratamento l√≥gico",
        text: "After a heart attack, arrhythmias predict death. <strong>Encainide and flecainide</strong> suppressed arrhythmias on ECG beautifully‚Äî85% reduction in premature ventricular contractions. The FDA approved them. Cardiologists prescribed them to hundreds of thousands of post-MI patients. The logic was irresistible: dangerous arrhythmias ‚Üí sudden death; suppress arrhythmias ‚Üí prevent death.",
        followup: "The CAST trial was designed to confirm what everyone already 'knew.' Instead, it delivered a verdict that stunned cardiology. Patients on anti-arrhythmic drugs died at <strong>3.6 times the rate</strong> of placebo. The trials were stopped early for harm. An estimated <strong>50,000 Americans died</strong> from drugs that perfectly fixed the surrogate (ECG) while causing the outcome (death). The evidence for arrhythmia suppression was HIGH certainty‚Äîbut it was indirect evidence for mortality. That indirectness killed 50,000 people."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìà", title: "Cen√°rio: O substituto perfeito",
        xp: 25,
        scenario: "Um novo medicamento para diabetes mostra redu√ß√£o dram√°tica da HbA1c (melhoria de 1,5% em compara√ß√£o com placebo). A empresa argumenta que, uma vez que a HbA1c √© um ‚Äúsubstituto validado‚Äù para resultados cardiovasculares, a certeza do benef√≠cio CV deve ser classificada como MODERADA. Ainda n√£o existem ensaios de resultados CV.",
        question: "Como voc√™ deve avaliar a certeza do benef√≠cio cardiovascular?",
        options: [
          { letter: "A", text: "MODERATE‚ÄîHbA1c is a validated surrogate", correct: false },
          { letter: "B", text: "HIGH‚Äî1.5% reduction is clinically meaningful", correct: false },
          { letter: "C", text: "LOW or VERY LOW‚Äîdowngrade for indirectness (surrogate outcome)", correct: true },
          { letter: "D", text: "Cannot rate until CV trials are conducted", correct: false }
        ],
        feedback: {
          correct: "Correct! ACCORD showed intensive HbA1c lowering <em>increased</em> deaths. Rosiglitazone lowered HbA1c while increasing heart attacks. Surrogate outcomes require downgrading for indirectness, no matter how 'validated' they seem. Patient-important outcomes are required for high certainty.",
          incorrect: "CAST drugs fixed ECGs while tripling deaths. ACCORD lowered HbA1c while increasing mortality. 'Validated surrogates' have repeatedly failed. GRADE requires downgrading one or two levels when only surrogate outcomes are measured."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "A trai√ß√£o da densidade √≥ssea", title: "When Stronger Bones Broke More",
        text: "Sodium fluoride increased bone mineral density dramatically‚Äî<strong>8% improvement per year</strong>. For osteoporosis, this seemed like a miracle. Bone density was the accepted surrogate for fracture risk. Higher density = fewer fractures. The math seemed inescapable.",
        followup: "Then came the trials measuring actual fractures. Sodium fluoride <strong>increased</strong> fracture rates despite improving bone density. The explanation: fluoride created dense but brittle bone‚Äîlike adding quantity without quality. The surrogate (density) moved in the right direction while the patient-important outcome (fractures) moved in the wrong direction. This case became a landmark in surrogate outcome skepticism."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ü¶¥", title: "Scenario: The Bone Drug Decision",
        xp: 25,
        scenario: "A new osteoporosis drug shows 4% improvement in bone mineral density at 2 years. The company presents evidence of reduced fractures, but the fracture trials used a different formulation and dose than the one being approved. The FDA asks you to rate certainty of fracture benefit for the approved formulation.",
        question: "What indirectness concern applies?",
        options: [
          { letter: "A", text: "No concern‚Äîbone density is a validated surrogate", correct: false },
          { letter: "B", text: "Indireto para interven√ß√£o ‚Äì formula√ß√£o/dose diferente foi testada", correct: true },
          { letter: "C", text: "Indirect for population‚Äîfracture trials may have different patients", correct: false },
          { letter: "D", text: "Indireto para o resultado ‚Äì as fraturas n√£o s√£o importantes para o paciente", correct: false }
        ],
        feedback: {
          correct: "Correto! A indireta pode aplicar-se √† interven√ß√£o, √† popula√ß√£o, ao comparador ou ao resultado. Aqui, a formula√ß√£o/dose testada para fraturas difere daquela que est√° sendo aprovada. N√£o podemos assumir equival√™ncia. Isto requer um rebaixamento para interven√ß√£o indireta.",
          incorrect: "A evid√™ncia de fratura vem de uma formula√ß√£o e dose diferentes. Estamos extrapolando do medicamento A na dose X para o medicamento A na dose Y. Isso √© interven√ß√£o indireta ‚Äì as evid√™ncias n√£o testam diretamente o que estamos aprovando."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "O c√°lculo da rosiglitazona", title: "FDA's 2.5 Million Patient Gamble",
        text: "In 2007, cardiologist Steven Nissen published a meta-analysis showing rosiglitazone (Avandia) increased heart attacks by <strong>43%</strong>. The drug had been prescribed to millions based on glucose control. But no large outcome trial had ever been required.",
        followup: "The FDA's logic had been: diabetes causes heart disease ‚Üí better glucose control should prevent it. That's <strong>indirectness</strong>‚Äîassuming a chain of causation without testing the final link. The FDA estimated rosiglitazone caused <strong>83,000 excess heart attacks</strong> before restrictions were imposed. The European Medicines Agency suspended it entirely. A drug approved on indirect evidence had harmed more patients than it helped."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üíä", title: "Cen√°rio: a lacuna frente a frente",
        xp: 25,
        scenario: "Voc√™ precisa comparar o medicamento A com o medicamento B para sua orienta√ß√£o. N√£o existem testes frente a frente. Voc√™ tem: Medicamento A versus placebo (RR 0,70) e Medicamento B versus placebo (RR 0,65) de ensaios separados em diferentes popula√ß√µes realizados com 10 anos de intervalo.",
        question: "What type of indirectness applies?",
        options: [
          { letter: "A", text: "No indirectness‚Äîwe can compare the two placebo-controlled estimates", correct: false },
          { letter: "B", text: "Indirect comparisons require downgrading‚Äîdifferent trials break randomization", correct: true },
          { letter: "C", text: "Apenas indireto para a popula√ß√£o, n√£o para compara√ß√£o", correct: false },
          { letter: "D", text: "Network meta-analysis solves this indirectness", correct: false }
        ],
        feedback: {
          correct: "Correct! Comparing across trials breaks randomization. Drug A's trial may have sicker patients, different background care, different outcome definitions. The RR difference (0.70 vs. 0.65) may reflect trial differences, not drug differences. GRADE calls this 'indirect comparison' and requires downgrading.",
          incorrect: "As compara√ß√µes indiretas s√£o fundamentalmente diferentes dos testes diretos. Quando comparamos o medicamento A versus placebo (ensaio 1) com o medicamento B versus placebo (ensaio 2), qualquer diferen√ßa entre os ensaios torna-se um fator de confus√£o. A metan√°lise de rede ajuda, mas n√£o elimina essa indireta."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "A Extrapola√ß√£o do Oseltamivir", title: "Do laborat√≥rio √† cl√≠nica e √† mentira",
        text: "Tamiflu (oseltamivir) was approved based on trials showing it reduced <strong>symptom duration by 21 hours</strong> in otherwise healthy adults. When pandemic flu threatened, governments extrapolated: if it shortens symptoms, it must prevent complications. If it works in healthy adults, it must work in high-risk patients.",
        followup: "Neither extrapolation was supported. Trials in <strong>high-risk patients</strong> (the ones who actually need protection) showed no benefit. Trials measuring <strong>hospitalizations and complications</strong> (the outcomes that matter) were never conducted‚Äîor never published. The ¬£473 million UK stockpile was based on indirect evidence: wrong population (healthy, not high-risk), wrong outcome (symptoms, not complications). The Cochrane review downgraded certainty for both types of indirectness."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üè•", title: "Cen√°rio: A Extrapola√ß√£o Populacional",
        xp: 25,
        scenario: "Um tratamento mostra benef√≠cios em ensaios com pacientes entre 18 e 65 anos sem comorbidades. Sua diretriz √© direcionada a idosos residentes em lares de idosos com m√∫ltiplas comorbidades. O tratamento tem raz√µes biologicamente plaus√≠veis para funcionar de forma diferente nos idosos (metabolismo alterado, intera√ß√µes medicamentosas).",
        question: "Voc√™ deve fazer o downgrade por indiretividade?",
        options: [
          { letter: "A", text: "No‚Äîage alone doesn't require downgrading", correct: false },
          { letter: "B", text: "Yes‚Äîbiological reasons for different effects in target population require downgrading", correct: true },
          { letter: "C", text: "Only if the elderly show different baseline risk", correct: false },
          { letter: "D", text: "Use a an√°lise de subgrupo dos ensaios originais", correct: false }
        ],
        feedback: {
          correct: "Correct! When there are biological reasons to expect different effects in the target population, downgrade for indirectness. Tamiflu worked in healthy adults but the question was about sick elderly patients‚Äîa population with very different biology. Extrapolation across populations with different biology requires downgrading.",
          incorrect: "Population indirectness applies when the trial population differs meaningfully from the guideline population, especially when there are biological reasons to expect different effects. Elderly with comorbidities may metabolize drugs differently, have drug interactions, and have different risk-benefit profiles."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "A trag√©dia do Torcetrapib", title: "$800 Million Buried in 82 Days",
        text: "Pfizer's torcetrapib was the most expensive drug development in history‚Äî<strong>$800 million</strong> over 15 years. It dramatically raised HDL cholesterol (the 'good' cholesterol) by 72%. The logic was irresistible: low HDL causes heart disease ‚Üí raising HDL should prevent it. Phase 2 trials showed perfect surrogate outcomes. Pfizer began building manufacturing plants before Phase 3 completed.",
        followup: "The ILLUMINATE trial enrolled <strong>15,067 patients</strong>. After just 82 days, the Data Safety Monitoring Board stopped the trial. Torcetrapib increased death by <strong>58%</strong> and cardiovascular events by 25%. The drug that perfectly improved HDL was killing patients. Pfizer's stock dropped $21 billion in one day. The entire HDL-raising hypothesis‚Äîbuilt on decades of surrogate evidence‚Äîcollapsed. No HDL-raising drug has ever prevented cardiovascular events. Surrogate perfection masked clinical catastrophe."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üíî", title: "Cen√°rio: O substituto perfeito",
        xp: 25,
        scenario: "Um novo medicamento aumenta o colesterol HDL em 80% ‚Äì mais do que qualquer agente anterior. A empresa argumenta: ‚ÄúProvamos que o HDL protege causalmente contra doen√ßas card√≠acas. Esta droga salvar√° milh√µes de vidas‚Äù. Eles solicitam aprova√ß√£o acelerada baseada apenas na melhoria do HDL.",
        question: "Based on the torcetrapib experience, what certainty applies to cardiovascular benefit?",
        options: [
          { letter: "A", text: "HIGH‚ÄîHDL is a validated causal risk factor", correct: false },
          { letter: "B", text: "MODERATE‚Äîstrong mechanistic support warrants some confidence", correct: false },
          { letter: "C", text: "LOW to VERY LOW‚ÄîHDL-raising has consistently failed to translate to outcomes", correct: true },
          { letter: "D", text: "Cannot rate until mechanism is fully understood", correct: false }
        ],
        feedback: {
          correct: "Correct! Torcetrapib, dalcetrapib, evacetrapib‚Äîevery HDL-raising drug has failed to prevent cardiovascular events despite dramatic surrogate improvement. The entire drug class teaches us: manipulating a surrogate doesn't guarantee clinical benefit. Evidence from this class requires serious downgrading for indirectness.",
          incorrect: "V√°rios medicamentos que aumentam o HDL demonstraram uma melhoria substituta dram√°tica, sem nenhum benef√≠cio cardiovascular (ou dano real). Esta classe de medicamentos provou definitivamente que a manipula√ß√£o do HDL n√£o se traduz em resultados. A rela√ß√£o substituta n√£o se mant√©m quando manipulada farmacologicamente."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "A revers√£o da eritropoietina", title: "When Better Blood Was Worse",
        text: "Pacientes com c√¢ncer e anemia sentem-se p√©ssimos ‚Äì fadiga, fraqueza, falta de ar. Os agentes estimuladores da eritropoietina (AEEs) aumentaram a hemoglobina e fizeram os pacientes se sentirem melhor. A qualidade de vida melhorou. O FDA aprovou ESAs para anemia relacionada ao c√¢ncer. Os oncologistas os prescreveram amplamente.",
        followup: "Then meta-analyses examining <strong>mortality</strong> emerged. Despite improving hemoglobin (surrogate) and quality of life, ESAs increased <strong>death by 10%</strong> and thromboembolic events by 57%. Patients felt better while dying faster. The FDA added a black box warning. ESA use plummeted. The lesson: even quality-of-life improvements can coexist with mortality harm. Surrogates that patients can feel aren't necessarily safer surrogates."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ü©∏", title: "Scenario: The Quality of Life Surrogate",
        xp: 25,
        scenario: "Um tratamento melhora drasticamente um substituto de sintoma ‚Äì os pacientes se sentem muito melhor, a energia melhora, a fun√ß√£o di√°ria aumenta. Os escores de qualidade de vida melhoram em 40%. N√£o existem dados de mortalidade. A empresa argumenta que esta √© uma 'evid√™ncia centrada no paciente' que deve receber alta certeza.",
        question: "What certainty applies to net clinical benefit?",
        options: [
          { letter: "A", text: "HIGH‚Äîpatient-reported outcomes matter most", correct: false },
          { letter: "B", text: "MODERATE‚Äîquality of life is a valid outcome", correct: false },
          { letter: "C", text: "LOW‚Äîimproved symptoms can coexist with mortality harm; need outcome data", correct: true },
          { letter: "D", text: "Depende da condi√ß√£o espec√≠fica", correct: false }
        ],
        feedback: {
          correct: "Correto! As ESAs melhoraram a qualidade de vida e aumentaram a mortalidade em 10%. Sentir-se melhor n√£o √© o mesmo que ser melhor. A melhora dos sintomas pode mascarar danos √† sobreviv√™ncia. O GRADE exige o rebaixamento da indireta quando os dados de mortalidade/danos graves est√£o ausentes, mesmo com resultados de sintomas positivos.",
          incorrect: "A experi√™ncia da ESA prova que os pacientes podem se sentir dramaticamente melhor enquanto morrem mais r√°pido. A melhoria da qualidade de vida √© real, mas n√£o garante benef√≠cios l√≠quidos. Sem dados sobre mortalidade e eventos adversos graves, a certeza deve permanecer baixa, independentemente da melhora dos sintomas."
        }
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Four Types of Indirectness",
        items: [
          "Population ‚Äî Trial patients differ from guideline patients",
          "Intervention ‚Äî Trial intervention differs from recommendation",
          "Comparador ‚Äî A compara√ß√£o dos ensaios difere da quest√£o cl√≠nica",
          "Outcome ‚Äî Trial measures surrogates instead of patient-important outcomes"
        ]
      }},
      { type: "quiz", theme: "dark", content: {
        question: "Por que os medicamentos antiarr√≠tmicos CAST mataram 50.000 pessoas apesar da evid√™ncia perfeita de supress√£o de arritmia?",
        options: [
          { text: "Os ensaios foram fraudulento", correct: false },
          { text: "O substituto (supress√£o de arritmia) n√£o previu o resultado (morte)", correct: true },
          { text: "Doctors used the drugs incorrectly", correct: false },
          { text: "A popula√ß√£o de pacientes foi diferente dos ensaios", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Exactly. The evidence for arrhythmia suppression was impeccable. The drugs did exactly what they were supposed to do on ECG. But suppressing arrhythmias didn't prevent death‚Äîit caused it through different mechanisms. This is indirectness for outcome: measuring surrogates instead of patient-important endpoints.",
          incorrect: "The trials were well-conducted. The drugs worked perfectly for their intended purpose (suppressing arrhythmias). The problem was indirectness: arrhythmia suppression (the measured outcome) didn't predict mortality (the outcome that matters). Surrogate outcomes can mislead even when evidence is methodologically perfect."
        }
      }}
    ]
  },
  {
    id: 6, title: "Imprecision", subtitle: "Dados insuficientes", xp: 150,
    slides: [
      { type: "title", theme: "dark", content: { title: "Imprecision", subtitle: "O quarto dom√≠nio: Temos o suficiente dados?" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Understand why wide confidence intervals undermine certainty",
          "Apply the 'Optimal Information Size' concept",
          "Recognize when 95% CIs cross clinical decision thresholds",
          "Decide when to downgrade for imprecision"
        ],
        tip: "Statistical significance is not enough‚Äîconfidence intervals must be clinically narrow."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "O PROWESS Mirage", title: "When 1,690 Deaths Weren't Enough",
        text: "In 2001, Eli Lilly's drotrecogin alfa (Xigris) was approved for severe sepsis based on the PROWESS trial. The trial showed <strong>6.1% absolute mortality reduction</strong>‚Äîfrom 30.8% to 24.7%. The FDA approved it despite concerns. Cost: $6,800 per treatment. Lilly projected billions in revenue.",
        followup: "Then came the confidence interval analysis. The 95% CI for mortality reduction ranged from <strong>1.9% to 10.4%</strong>. The benefit might be huge (10.4%) or clinically marginal (1.9%). With a drug this expensive and risky (increased bleeding), that uncertainty mattered. Subsequent trials failed to replicate PROWESS. The ADDRESS trial in less severe sepsis showed <strong>no benefit</strong>. The PROWESS-SHOCK trial confirmed <strong>no mortality benefit</strong> even in severe sepsis. In 2011, Lilly withdrew Xigris worldwide. A decade of use, billions spent, and the imprecision had warned us from the start."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìê", title: "Scenario: The Wide Confidence Interval",
        xp: 25,
        scenario: "A trial shows a new treatment reduces mortality from 20% to 14%‚Äîa 6% absolute reduction (RR 0.70, p=0.04). However, the 95% CI for absolute risk reduction is 0.5% to 11.5%. The lower bound (0.5%) is below your minimum clinically important difference of 2%.",
        question: "Voc√™ deve fazer downgrade por imprecis√£o?",
        options: [
          { letter: "A", text: "N√£o‚Äîo resultado √© estatisticamente significativo", correct: false },
          { letter: "B", text: "No‚Äîthe point estimate shows clinically meaningful benefit", correct: false },
          { letter: "C", text: "Yes‚Äîthe CI includes clinically unimportant effects", correct: true },
          { letter: "D", text: "Sim‚Äîo IC inclui danos", correct: false }
        ],
        feedback: {
          correct: "Correto! A signific√¢ncia estat√≠stica n√£o garante precis√£o cl√≠nica. Se o verdadeiro efeito puder ser t√£o pequeno quanto 0,5% (abaixo da diferen√ßa m√≠nima importante), voc√™ n√£o poder√° recomendar o tratamento com seguran√ßa. O GRADE exige o rebaixamento quando os ICs ultrapassam os limites de decis√£o cl√≠nica, e n√£o apenas o nulo.",
          incorrect: "O limite inferior do IC (0,5%) fica abaixo da diferen√ßa m√≠nima clinicamente importante (2%). Isto significa que o verdadeiro efeito pode ser demasiado pequeno para justificar os custos/riscos do tratamento. A signific√¢ncia estat√≠stica n√£o √© suficiente ‚Äì os ICs devem excluir efeitos clinicamente sem import√¢ncia para obter alta certeza."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "O tamanho ideal da informa√ß√£o", title: "Why Sample Size Matters for Certainty",
        text: "Consider a simple thought experiment: You flip a coin 4 times and get 3 heads (75%). Would you bet your house that the coin is biased? Now flip 1,000 times and get 750 heads. Same proportion‚Äîbut utterly different certainty.",
        followup: "GRADE uses the <strong>Optimal Information Size (OIS)</strong> concept. This asks: 'How many events would a single adequately-powered trial need to reliably detect this effect?' If your meta-analysis has fewer events than the OIS, you're in the position of the person who flipped 4 coins‚Äîthe proportion might be right, but you don't have enough data to be confident. For mortality outcomes, OIS is typically <strong>200-400 events</strong>. Many celebrated meta-analyses have far fewer."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üî¢", title: "Cen√°rio: a pequena meta-an√°lise",
        xp: 25,
        scenario: "A meta-analysis of 8 RCTs (total n=1,200) shows a treatment prevents death with RR 0.65 (95% CI 0.45-0.95). The total number of deaths across all trials is 87. The pooled estimate is statistically significant. Your OIS calculation suggests 300 events would be needed.",
        question: "Voc√™ deve fazer downgrade por imprecis√£o?",
        options: [
          { letter: "A", text: "No‚Äîstatistical significance means adequate precision", correct: false },
          { letter: "B", text: "No‚Äî8 RCTs provide adequate power through meta-analysis", correct: false },
          { letter: "C", text: "Yes‚Äî87 events is well below the OIS of 300", correct: true },
          { letter: "D", text: "Somente se o IC cruzar 1.0", correct: false }
        ],
        feedback: {
          correct: "Correto! 87 eventos versus OIS de 300 significa que temos menos de 30% das informa√ß√µes necess√°rias. A estimativa pode estar correta, mas estamos em territ√≥rio de ‚Äúamostra pequena‚Äù, onde a varia√ß√£o aleat√≥ria pode produzir efeitos de apar√™ncia dram√°tica, mas n√£o confi√°veis. GRADE requer downgrade quando os eventos est√£o muito abaixo do OIS.",
          incorrect: "A meta-an√°lise n√£o cria informa√ß√µes magicamente. 8 pequenas tentativas com 87 eventos no total n√£o equivalem a uma grande tentativa com 300 eventos. A signific√¢ncia estat√≠stica √© provavelmente fr√°gil ‚Äì de qualquer forma, alguns acontecimentos mudariam a conclus√£o. OIS fornece uma verifica√ß√£o da realidade sobre a adequa√ß√£o da amostra."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "A revers√£o do hidroxietilamido", title: "When 10,000 Patients Weren't Enough... Then Were",
        text: "Hydroxyethyl starch (HES) fluids were used for decades in critically ill patients. Early meta-analyses with few events showed possible benefit. Then came the large trials: <strong>6S trial (798 patients)</strong>, <strong>CHEST trial (7,000 patients)</strong>, <strong>CRISTAL trial (2,857 patients)</strong>.",
        followup: "The large trials showed HES <strong>increased mortality and kidney failure</strong>. The earlier 'positive' evidence had been imprecise‚Äîconfidence intervals that allowed for benefit also allowed for the substantial harm that large trials eventually detected. The European Medicines Agency suspended HES for critical illness. Imprecise evidence had allowed a harmful intervention to persist for years."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚ö†Ô∏è", title: "Scenario: The Borderline Mortality Signal",
        xp: 25,
        scenario: "Uma meta-an√°lise mostra um RR de morte de 1,25 (IC 95% 0,98-1,60) com um tratamento. O resultado ‚Äútend√™ncia para danos‚Äù, mas n√£o √© estatisticamente significativo. Sua diretriz deve decidir se recomenda este tratamento para uma condi√ß√£o n√£o fatal onde existem alternativas.",
        question: "How should imprecision affect your recommendation?",
        options: [
          { letter: "A", text: "O tratamento √© seguro‚ÄîIC inclui 1,0", correct: false },
          { letter: "B", text: "The treatment is harmful‚Äîpoint estimate shows 25% increase", correct: false },
          { letter: "C", text: "S√©ria incerteza sobre danos‚ÄîCI consistente com aumento de mortalidade de at√© 60%", correct: true },
          { letter: "D", text: "Need more trials before any conclusion", correct: false }
        ],
        feedback: {
          correct: "Correct! The upper bound (1.60) represents a 60% mortality increase. For a non-fatal condition with alternatives, that possibility should drive decision-making. 'Not statistically significant' doesn't mean safe‚Äîit means we can't rule out substantial harm. GRADE incorporates the entire CI, not just p-values.",
          incorrect: "O limite superior do IC de 1,60 significa que n√£o podemos descartar 60% de aumento na mortalidade. Para um tratamento que aborde uma condi√ß√£o n√£o fatal onde existam alternativas, esta incerteza sobre danos graves deve dominar a decis√£o. N√£o signific√¢ncia estat√≠stica ‚â† seguran√ßa."
        }
      }},
      { type: "concept", theme: "dark", content: {
        title: "O √çndice de Fragilidade",
        subtitle: "How stable is statistical significance?",
        text: "The fragility index asks: 'How many patients would need to have had a different outcome to make this result non-significant?' A fragility index of 3 means if just 3 patients had different outcomes, the p-value would cross 0.05. Many published 'significant' findings have fragility indices under 10.",
        highlight: "Um ensaio com √≠ndice de fragilidade de 5 significa que o resultado 'significativo' depende de menos pacientes do que aqueles que ficam sentados na sala de espera do seu consult√≥rio."
      }},
      { type: "story", theme: "dark", content: {
        label: "O √°cido tranex√¢mico Triunfo", title: "When Precision Demanded 20,000 Patients",
        text: "Could tranexamic acid (TXA) reduce death from bleeding in trauma? Early trials were suggestive but imprecise. The <strong>CRASH-2 trial</strong> took a different approach: enroll enough patients to get a precise answer.",
        followup: "<strong>20,211 patients</strong> across 274 hospitals in 40 countries. Result: TXA reduced death from bleeding from 5.7% to 4.9%‚Äîa 0.8% absolute reduction. The 95% CI was <strong>0.3% to 1.3%</strong>. Finally, precision: the entire CI showed clinically meaningful benefit. The WHO added TXA to its Essential Medicines List. The precision wasn't just scientific‚Äîit changed global policy because decision-makers could trust the narrow bounds."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚úì", title: "Scenario: The Precise But Small Effect",
        xp: 25,
        scenario: "A mega-trial (n=40,000) shows a treatment reduces mortality with RR 0.95 (95% CI 0.91-0.99). The result is statistically significant and the CI is narrow. However, the absolute risk reduction is 0.3% (NNT = 333). Your minimum clinically important difference for this outcome is 0.2%.",
        question: "Voc√™ deve fazer downgrade por imprecis√£o?",
        options: [
          { letter: "A", text: "Yes‚Äîthe effect is too small to matter clinically", correct: false },
          { letter: "B", text: "No‚Äîthe narrow CI excludes clinically unimportant effects", correct: true },
          { letter: "C", text: "Yes‚ÄîNNT of 333 suggests imprecision", correct: false },
          { letter: "D", text: "Cannot determine without knowing the OIS", correct: false }
        ],
        feedback: {
          correct: "Correct! The entire CI (0.91-0.99) lies below 1.0, and the corresponding absolute effects (0.1%-0.5%) are all above your minimum important difference of 0.2%. Small but precise effects that meet the clinical threshold don't require downgrading for imprecision. The issue is clinical judgment about whether the effect justifies intervention.",
          incorrect: "A imprecis√£o tem a ver com intervalos de confian√ßa, n√£o com o tamanho do efeito. Um efeito pequeno, mas estimado com precis√£o, que exclui valores clinicamente sem import√¢ncia, n√£o √© impreciso ‚Äì √© apenas pequeno. Se uma redu√ß√£o absoluta de 0,3% justifica o tratamento √© um julgamento de valores, n√£o uma quest√£o de precis√£o.<"
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "A controv√©rsia do J√öPITER", title: "When 17,802 Patients Still Weren't Enough",
        text: "The JUPITER trial enrolled <strong>17,802 patients</strong> to test rosuvastatin for primary prevention. After just 1.9 years (planned: 5 years), it was stopped early for 'overwhelming benefit.' Heart attacks were reduced by 54%! Headlines celebrated. Rosuvastatin prescriptions soared.",
        followup: "But critics noticed problems. Only <strong>68 heart attacks</strong> total across both groups‚Äîfragility index of just 4. The wide confidence intervals (0.29-0.73) reflected genuine uncertainty. Early stopping inflates effect sizes by 30% on average. And absolute risk reduction was just <strong>0.35%</strong> over 1.9 years‚ÄîNNT of 286. A 'landmark' trial with thousands of patients still had imprecision concerns because it was stopped before enough events accumulated. Large n doesn't guarantee precision when event rates are low."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚èπÔ∏è", title: "Cen√°rio: o teste interrompido precocemente",
        xp: 25,
        scenario: "A large trial (n=10,000) is stopped early after 2 years (planned: 5) for 'overwhelming efficacy.' The treatment shows 50% relative risk reduction. However, only 45 total events occurred, and the original planned stopping boundary was crossed by just 2 events.",
        question: "How should early stopping affect certainty assessment?",
        options: [
          { letter: "A", text: "No concern‚Äîlarge sample size ensures precision", correct: false },
          { letter: "B", text: "Rebaixamento por imprecis√£o - a parada antecipada aumenta os efeitos e cria fragilidade descobertas", correct: true },
          { letter: "C", text: "Upgrade certainty‚Äîstopping early proves the effect is large", correct: false },
          { letter: "D", text: "Neutral‚Äîmonitoring rules are pre-specified", correct: false }
        ],
        feedback: {
          correct: "Correct! Early stopping typically inflates effect sizes by 30%. With only 45 events and crossing the boundary by 2, this finding is extremely fragile. Large n doesn't help when event rates are low‚Äîyou need enough events, not just patients. GRADE recommends downgrading for trials stopped early with few events.",
          incorrect: "Os ensaios interrompidos precocemente superestimam sistematicamente os efeitos. Com 45 eventos e um √≠ndice de fragilidade de ~2, a redu√ß√£o de 50% desapareceria se apenas 2 pacientes tivessem resultados diferentes. A amostra grande √© irrelevante - s√£o os eventos que geram precis√£o."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "A li√ß√£o ISIS-4", title: "Quando 58.000 pacientes responderam √† pergunta",
        text: "After GISSI-2 suggested magnesium might reduce mortality in heart attack patients, smaller trials showed inconsistent results. The <strong>ISIS-4</strong> trial was designed to end the debate: <strong>58,050 patients</strong>, the largest heart attack trial ever. If magnesium worked, this trial would prove it.",
        followup: "Result: magnesium showed <strong>no benefit</strong> (mortality 7.64% vs. 7.24%, NS). The pooled meta-analysis before ISIS-4 had shown significant benefit‚Äîbut was driven by small trials with imprecise estimates. When finally tested with adequate precision, the effect vanished. This pattern‚Äîdramatic effects in small trials, null effects in large trials‚Äîis so common it has a name: 'the winner's curse.' Small trials select for extreme results; large trials reveal reality."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üé≤", title: "Scenario: Small Trial Meta-Analysis vs. Large Trial",
        xp: 25,
        scenario: "A meta-analysis of 15 small trials (total n=2,000, 180 events) shows significant mortality benefit (RR 0.65, p=0.001). A single large trial (n=15,000, 2,100 events) shows no benefit (RR 0.98, p=0.61). The meta-analysis was published first.",
        question: "Como voc√™ deve avaliar essas descobertas conflitantes?",
        options: [
          { letter: "A", text: "Average them‚Äîmore trials means more evidence", correct: false },
          { letter: "B", text: "Prefer the meta-analysis‚Äî15 trials beat 1 trial", correct: false },
          { letter: "C", text: "Prefira o estudo grande - ele tem 10x mais eventos e precis√£o", correct: true },
          { letter: "D", text: "Declarar evid√™ncias inconclusivas", correct: false }
        ],
        feedback: {
          correct: "Correto! 2.100 eventos versus 180 eventos significa que o grande estudo tem aproximadamente 12 vezes mais informa√ß√µes. Metan√°lises de pequenos ensaios s√£o propensas a vieses de publica√ß√£o e √† maldi√ß√£o do vencedor. Quando um estudo grande e com poder adequado contradiz metan√°lises de estudos pequenos, o estudo grande geralmente revela a verdade.",
          incorrect: "ISIS-4 taught this lesson. Small trials showed magnesium benefit; the 58,000-patient trial showed nothing. Events determine precision, not number of trials. Publication bias and random variation create false signals in small trial meta-analyses that large trials correct."
        }
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Imprecision Assessment Checklist",
        items: [
          "Does the 95% CI cross clinically important thresholds?",
          "O IC cruza benef√≠cios e danos?",
          "O n√∫mero total de eventos est√° abaixo do tamanho ideal de informa√ß√µes?",
          "Qual √© o √≠ndice de fragilidade da chave descobertas?",
          "Would the upper or lower bound change clinical decision-making?"
        ]
      }},
      { type: "quiz", theme: "dark", content: {
        question: "Why does GRADE require downgrading when confidence intervals cross 'clinical decision thresholds' even if statistically significant?",
        options: [
          { text: "As conven√ß√µes estat√≠sticas s√£o arbitr√°rias", correct: false },
          { text: "The true effect might be too small (or too harmful) to justify treatment", correct: true },
          { text: "P-values don't account for sample size", correct: false },
          { text: "Confidence intervals are more accurate than p-values", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Exatamente. Se um tratamento reduz ‚Äúsignificativamente‚Äù a mortalidade, mas o IC inclui efeitos demasiado pequenos para justificar o custo/risco ‚Äì ou inclui danos substanciais ‚Äì n√£o podemos recomend√°-lo com confian√ßa. O GRADE avalia a precis√£o em rela√ß√£o aos limites cl√≠nicos, n√£o √†s conven√ß√µes estat√≠sticas.",
          incorrect: "As decis√µes cl√≠nicas exigem saber se o verdadeiro efeito √© grande o suficiente para ter import√¢ncia. Um resultado estatisticamente significativo com um IC abrangendo ‚Äútrivialmente √∫til‚Äù a ‚Äúsubstancialmente prejudicial‚Äù n√£o orienta o tratamento. GRADE usa limites cl√≠nicos porque √© isso que as decis√µes exigem."
        }
      }}
    ]
  },
  {
    id: 7, title: "Publication Bias", subtitle: "A evid√™ncia invis√≠vel", xp: 160,
    slides: [
      { type: "title", theme: "red-bg", content: { title: "Publication Bias", subtitle: "O quinto dom√≠nio: Que evid√™ncias nunca chegaram at√© n√≥s?" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Entenda como os ensaios negativos desaparecem da literatura",
          "Interpret funnel plots and their limitations",
          "Recognize when publication bias likely distorts evidence",
          "Decide when to downgrade certainty for publication bias"
        ],
        tip: "A evid√™ncia mais perigosa √© a evid√™ncia que voc√™ nunca veja."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "O engano da paroxetina", title: "GlaxoSmithKline's Hidden Children",
        text: "In the early 2000s, GSK marketed paroxetine (Paxil) for adolescent depression. The published evidence looked convincing. Study 329, published in the <em>Journal of the American Academy of Child and Adolescent Psychiatry</em>, reported paroxetine was <strong>'generally well tolerated and effective.'</strong> Thousands of teenagers were prescribed the drug.",
        followup: "Then lawsuits forced GSK to release internal documents. Study 329 had actually shown paroxetine was <strong>no better than placebo</strong> and increased suicidal behavior. GSK had conducted other trials‚Äîalso negative‚Äîthat were never published. The published paper had been ghost-written by a medical communications company. When all studies were combined, the truth emerged: paroxetine didn't work for teen depression and was dangerous. The published literature had been systematically manipulated. Publication bias wasn't passive‚Äîit was manufactured."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìö", title: "Cen√°rio: A literatura totalmente positiva",
        xp: 25,
        scenario: "Uma meta-an√°lise inclui 12 ensaios financiados pela ind√∫stria de um novo antidepressivo - todos mostrando benef√≠cios. O gr√°fico do funil parece sim√©trico. Um colega observa que os registros da FDA mostram que a empresa realizou 8 ensaios adicionais que nunca foram publicados. Voc√™ n√£o pode acessar os dados n√£o publicados.",
        question: "Voc√™ deve fazer downgrade devido ao vi√©s de publica√ß√£o?",
        options: [
          { letter: "A", text: "N√£o, o gr√°fico de funil √© sim√©trico", correct: false },
          { letter: "B", text: "N√£o, s√≥ podemos julgar as evid√™ncias existentes", correct: false },
          { letter: "C", text: "Yes‚Äîdocumented unpublished trials suggest selective reporting", correct: true },
          { letter: "D", text: "Solicite os dados antes de decidir", correct: false }
        ],
        feedback: {
          correct: "Correct! The funnel plot only shows published studies‚Äîit can't detect missing studies. Knowing that 8 unpublished trials exist is strong evidence of publication bias. Paroxetine's symmetric funnel plot concealed hidden negative trials. GRADE downgrades when there's direct evidence of unpublished studies.",
          incorrect: "Os gr√°ficos de funil mostram apenas o que foi publicado. Se os ensaios negativos forem sistematicamente suprimidos (como acontece com a paroxetina), o funil pode parecer perfeito, ao mesmo tempo que esconde evid√™ncias cruciais. Os registros da FDA que mostram ensaios n√£o publicados s√£o evid√™ncia direta de vi√©s de publica√ß√£o."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "O bloqueio do oseltamivir", title: "Five Years to See the Truth",
        text: "The Cochrane Collaboration spent <strong>five years</strong> fighting Roche for Tamiflu (oseltamivir) data. Published trials showed reduced complications. Governments stockpiled billions of dollars worth of the drug. But Cochrane noticed discrepancies: study reports didn't match clinical study reports.",
        followup: "When Roche finally released the data in 2013, the missing <strong>60% of patient data</strong> revealed the truth. Published trials had reported 'complications' without proper definitions. Unpublished data showed adverse events were underreported. The updated Cochrane review: Tamiflu reduced symptoms by less than a day and had <strong>no proven effect on hospitalization or complications</strong>. Five years. Billions of dollars. And the published literature had been a carefully curated selection."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìä", title: "Cen√°rio: o funil assim√©trico",
        xp: 25,
        scenario: "A funnel plot shows clear asymmetry‚Äîsmall studies cluster toward positive effects while negative small studies are absent. Egger's test is statistically significant (p=0.01). The meta-analysis includes 25 trials with a pooled OR of 0.65 (significant benefit).",
        question: "Como isso deve afetar sua classifica√ß√£o de certeza?",
        options: [
          { letter: "A", text: "No effect‚ÄîEgger's test has poor specificity", correct: false },
          { letter: "B", text: "Downgrade one level‚Äîasymmetry suggests missing negative small studies", correct: true },
          { letter: "C", text: "Excluir pequenos estudos e reanalisar", correct: false },
          { letter: "D", text: "Asymmetry could be small-study effects, not publication bias", correct: false }
        ],
        feedback: {
          correct: "Correct! Significant funnel asymmetry with missing negative small studies is classic publication bias. Small negative studies are less likely to be published than small positive ones. Egger's test p=0.01 supports genuine asymmetry. GRADE requires downgrading when funnel asymmetry is clearly present.",
          incorrect: "While asymmetry has multiple causes, missing negative small studies is the most common pattern. The scenario describes classic publication bias: small positive studies published, small negative studies missing. This requires downgrading even if the exact cause is uncertain."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "O esc√¢ndalo da reboxetina", title: "74% of Data Hidden",
        text: "Reboxetine, an antidepressant approved in Europe, had <strong>74% of patient data</strong> from clinical trials never published. The published literature showed the drug worked. Regulatory agencies approved it. Doctors prescribed it to thousands of patients.",
        followup: "German researchers obtained the unpublished data through freedom of information requests. When all data was combined, reboxetine was <strong>no better than placebo</strong> and caused more side effects than other antidepressants. The published literature‚Äîbased on only 26% of the data‚Äîhad created a complete fiction. A drug that didn't work and caused harm had been sold for years because three-quarters of the evidence was invisible."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üóÉÔ∏è", title: "Cen√°rio: a lacuna no registro",
        xp: 25,
        scenario: "Voc√™ est√° avaliando ensaios de um medicamento contra o c√¢ncer. ClinicalTrials.gov mostra que 15 ensaios foram registrados e conclu√≠dos entre 2010-2018. Sua busca sistem√°tica encontra apenas 9 artigos publicados. Os 6 ensaios n√£o publicados foram todos menores do que os publicados.",
        question: "O que voc√™ deve concluir sobre o vi√©s de publica√ß√£o?",
        options: [
          { letter: "A", text: "Sem vi√©s ‚Äì ensaios menores geralmente s√£o estudos piloto", correct: false },
          { letter: "B", text: "N√£o est√° claro ‚Äì n√£o sabemos os resultados de ensaios n√£o publicados ensaios", correct: false },
          { letter: "C", text: "High likelihood of bias‚Äî40% of completed trials unpublished, all smaller ones", correct: true },
          { letter: "D", text: "Request unpublished results before rating", correct: false }
        ],
        feedback: {
          correct: "Correct! 40% unpublished rate‚Äîand specifically the smaller trials‚Äîis a red flag. Small trials showing positive results get published; small trials showing nothing often don't. This pattern inflates pooled estimates. GRADE recognizes registry-publication gaps as strong evidence of publication bias.",
          incorrect: "Seis dos 15 ensaios conclu√≠dos (40%) nunca foram publicados ‚Äì e todos eram estudos menores. Este √© exatamente o padr√£o que inflaciona as meta-an√°lises: pequenos ensaios negativos desaparecem. N√£o podemos esperar indefinidamente por dados n√£o publicados - devemos reconhecer que o preconceito existe."
        }
      }},
      { type: "stats", theme: "dark", content: {
        title: "A escala de evid√™ncias ocultas",
        stats: [
          { value: "50%", label: "Trials never published" },
          { value: "74%", label: "Dados de reboxetina ocultos" },
          { value: "60%", label: "Dados de Tamiflu n√£o divulgados" },
          { value: "31%", label: "Outcomes switched" }
        ],
        caption: "A literatura publicada representa uma sele√ß√£o com curadoria, n√£o completa evid√™ncia."
      }},
      { type: "concept", theme: "dark", content: {
        title: "Why Funnel Plots Aren't Enough",
        subtitle: "Detectando o indetect√°vel",
        text: "Funnel plots can only show what's published. They cannot detect:<br>‚Ä¢ Entire drugs that failed in trials and were never developed further<br>‚Ä¢ Studies with outcome switching (positive outcomes published, negative ones hidden)<br>‚Ä¢ Industry studies kept confidential<br>‚Ä¢ Studies published in inaccessible journals",
        highlight: "When publication bias is well-executed, it leaves no visible trace in the published literature."
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Publication Bias Red Flags",
        items: [
          "All or most trials industry-funded",
          "Trial registries show unpublished completed trials",
          "Assimetria do gr√°fico de funil com pequenos estudos negativos ausentes",
          "Outcomes in publications differ from registered protocols",
          "Large effects in meta-analysis contradicted by single large trial"
        ]
      }},
      { type: "quiz", theme: "dark", content: {
        question: "Por que o vi√©s de publica√ß√£o com paroxetina para depress√£o em adolescentes passou despercebido por anos?",
        options: [
          { text: "Os estudos foram bem conduzido", correct: false },
          { text: "Os ensaios negativos foram ocultados e o ensaio positivo foi escrito para deturpar os resultados", correct: true },
          { text: "The drug genuinely worked in some patients", correct: false },
          { text: "As ag√™ncias reguladoras n√£o revisaram os dados", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Exatamente. A GSK escondeu ensaios negativos e contratou uma empresa de comunica√ß√µes m√©dicas para redigir o Estudo 329 de uma forma que fizesse a paroxetina parecer eficaz. O vi√©s de publica√ß√£o foi deliberado e sistem√°tico ‚Äì vis√≠vel apenas quando a√ß√µes judiciais for√ßaram a divulga√ß√£o.",
          incorrect: "O engano foi ativo, n√£o passivo. A GSK sabia que a paroxetina n√£o funcionava no tratamento da depress√£o adolescente e no aumento do comportamento suicida. Eles enterraram ensaios negativos e deturparam o ensaio publicado. Os m√©todos tradicionais de detec√ß√£o n√£o conseguiram encontrar o que foi deliberadamente escondido."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "A Ilus√£o Antidepressiva", title: "Turner's 94 Trial Revelation",
        text: "In 2008, Dr. Erick Turner at the FDA did something unprecedented: he compared <strong>74 FDA-registered antidepressant trials</strong> to what was actually published. The FDA had seen all trials‚Äîpositive and negative. The literature had seen a carefully curated selection.",
        followup: "The results were damning. Of 38 positive trials, <strong>37 were published</strong>. Of 36 negative or questionable trials, only <strong>3 were published as negative</strong>‚Äî22 were never published, and 11 were published but 'spun' to appear positive. The published literature showed antidepressants were effective in 94% of trials. The FDA data showed 51%. Effect sizes in publications were <strong>32% larger</strong> than reality. An entire drug class had its efficacy inflated by systematic publication bias."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üíä", title: "Cen√°rio: A Literatura Seletiva",
        xp: 25,
        scenario: "You're assessing antidepressants for a guideline. The published literature shows 12 of 15 trials are positive. However, you discover FDA databases listing 8 additional completed trials that were never published. The published effect size is d=0.50.",
        question: "Como voc√™ deve ajustar sua avalia√ß√£o de certeza?",
        options: [
          { letter: "A", text: "Use only published trials‚Äîunpublished data isn't peer-reviewed", correct: false },
          { letter: "B", text: "Downgrade significantly‚Äî8 unpublished trials likely changes the effect size substantially", correct: true },
          { letter: "C", text: "Assume unpublished trials showed similar results", correct: false },
          { letter: "D", text: "Request unpublished data before making any assessment", correct: false }
        ],
        feedback: {
          correct: "Correto! A an√°lise de Turner mostrou que os tamanhos dos efeitos publicados foram 32% inflacionados. Oito ensaios n√£o publicados de um total de 23 (35% ocultos) significam que sua estimativa de efeito provavelmente √© substancialmente tendenciosa. Fa√ßa o downgrade devido ao vi√©s de publica√ß√£o e observe que o verdadeiro efeito √© provavelmente menor do que as estimativas publicadas.",
          incorrect: "A literatura sobre antidepressivos mostrou 94% de ensaios positivos em publica√ß√µes versus 51% nos dados da FDA. Ensaios n√£o publicados s√£o sistematicamente negativos. Assumir que eles s√£o semelhantes aos ensaios publicados contradiz d√©cadas de evid√™ncias sobre padr√µes de vi√©s de publica√ß√£o."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "O desastre RECORD", title: "When a Safety Study Hid Safety Signals",
        text: "After Avandia's cardiovascular concerns emerged, GSK designed RECORD‚Äîa 'cardiovascular safety study' of rosiglitazone. The study enrolled <strong>4,447 patients</strong> and ran for 5+ years. It was specifically designed to assess cardiovascular safety. The published conclusion: 'Rosiglitazone did not significantly increase cardiovascular risk.'",
        followup: "An FDA re-analysis told a different story. RECORD had serious adjudication problems‚Äî<strong>35% of potential cardiovascular events weren't properly evaluated</strong>. Some patients' events were classified as 'non-cardiac' when records suggested otherwise. The study designed to answer the safety question had been conducted in ways that systematically underdetected the very events it was supposed to measure. The publication bias wasn't in what studies were published‚Äîit was in how the study itself was designed and analyzed to produce a publishable 'negative' safety finding."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üîç", title: "Cen√°rio: O estudo de seguran√ßa 'tranquilizador'",
        xp: 25,
        scenario: "A drug with suspected harm has a 'definitive' safety study published showing no increased risk. However, you notice: outcomes were adjudicated by company employees, 30% of potential events were excluded as 'protocol deviations,' and the comparison group had higher baseline risk.",
        question: "Como essas caracter√≠sticas metodol√≥gicas devem afetar sua interpreta√ß√£o?",
        options: [
          { letter: "A", text: "Aceite o garantia - o estudo foi projetado especificamente para seguran√ßa", correct: false },
          { letter: "B", text: "Be skeptical‚Äîsystematic bias in outcome ascertainment can hide real signals", correct: true },
          { letter: "C", text: "Partially reassured‚Äîsome bias doesn't eliminate all value", correct: false },
          { letter: "D", text: "Ignorar e aguardar replica√ß√£o independente", correct: false }
        ],
        feedback: {
          correct: "Correto! A RECORD ensinou-nos que ‚Äúestudos de seguran√ßa‚Äù podem ser concebidos para n√£o encontrar danos. A adjudica√ß√£o da empresa, as exclus√µes seletivas e as compara√ß√µes favor√°veis ‚Äã‚Äãpodem subdetectar sistematicamente eventos adversos. Um estudo de seguran√ßa 'negativo' com essas caracter√≠sticas fornece falsa garantia.",
          incorrect: "Um estudo de seguran√ßa elaborado e adjudicado pela empresa com produto suspeito apresenta conflitos √≥bvios. A taxa de n√£o avalia√ß√£o de 35% da RECORD significava que os eventos n√£o estavam sendo contados adequadamente. 'Projetado para seguran√ßa' n√£o tem sentido se o design permitir que o dano escape da detec√ß√£o."
        }
      }}
    ]
  },
  {
    id: 8, title: "Upgrading Factors", subtitle: "When observational evidence earns trust", xp: 140,
    slides: [
      { type: "title", theme: "green-bg", content: { title: "Upgrading Factors", subtitle: "When observation rivals randomization" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Understand the three GRADE upgrading factors",
          "Learn when large effects can overcome confounding",
          "Recognize dose-response gradients as evidence of causation",
          "Apply 'all plausible confounders' reasoning"
        ],
        tip: "Upgrading is rare‚Äîbut sometimes observational evidence is unassailable."
      }},
      { type: "story", theme: "green-bg", content: {
        label: "A Prova de Fumar", title: "How 30x Risk Silenced Doubt",
        text: "In 1950, Richard Doll and Austin Bradford Hill published their case-control study: smokers had <strong>30 times higher lung cancer rates</strong> than non-smokers. The tobacco industry demanded RCTs‚Äîknowing they were impossible. 'Correlation isn't causation,' they insisted. 'Where's the randomized evidence?'",
        followup: "But the effect size spoke for itself. For confounding to explain a 30-fold increase, some unmeasured factor would need to cause both smoking and lung cancer with extraordinary strength‚Äîand be distributed perfectly across populations, generations, and geographies. No such confounder has ever been found. The evidence was upgraded from LOW to HIGH. GRADE recognizes that some effects are too large for confounding to explain."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìà", title: "Cen√°rio: O Grande Efeito",
        xp: 25,
        scenario: "Um estudo observacional mostra que um procedimento cir√∫rgico reduz a mortalidade de 80% a 10% - um risco relativo de 0,125 (redu√ß√£o relativa de 87,5%). N√£o existem ensaios cl√≠nicos randomizados porque suspender o tratamento seria anti√©tico dado o dram√°tico benef√≠cio observado.",
        question: "Esta evid√™ncia deve ser atualizada para obter um grande efeito?",
        options: [
          { letter: "A", text: "N√£o ‚Äì a evid√™ncia observacional n√£o pode ser atualizada", correct: false },
          { letter: "B", text: "Yes‚ÄîRR 0.125 is so large that confounding alone is implausible", correct: true },
          { letter: "C", text: "Somente se o estudo for bem projetado", correct: false },
          { letter: "D", text: "Only if dose-response is also present", correct: false }
        ],
        feedback: {
          correct: "Correct! RR 0.125 (or 8-fold relative reduction) is in the range where confounding alone is implausible. No unmeasured confounder could realistically reduce mortality from 80% to 10%. GRADE upgrades for large effects when RR < 0.5 or > 2, with additional upgrading for very large effects (RR < 0.2 or > 5).",
          incorrect: "Efeitos t√£o grandes s√£o essencialmente √† prova de RCT. Nenhum fator de confus√£o poderia explicar de forma plaus√≠vel uma redu√ß√£o relativa de 87,5%. Os p√°ra-quedas nunca foram testados em ensaios cl√≠nicos randomizados, mas n√£o temos d√∫vidas de que funcionam ‚Äì o tamanho do efeito √© evidente. GRADE permite a atualiza√ß√£o para efeitos muito grandes para serem explicados por confus√£o."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "A descoberta do folato", title: "Neural Tube Defects Prevented",
        text: "Na d√©cada de 1980, estudos observacionais sugeriram que a suplementa√ß√£o de folato prevenia defeitos do tubo neural (DTNs), como espinha b√≠fida. Mas como algu√©m poderia ter certeza? A confus√£o parecia inevit√°vel ‚Äì mulheres que tomam vitaminas s√£o provavelmente mais saud√°veis ‚Äã‚Äãem muitos aspectos.",
        followup: "Three upgrading factors came together. <strong>Large effect:</strong> Folate reduced NTDs by 70-80%. <strong>Dose-response:</strong> Higher folate levels correlated with lower NTD risk in a clear gradient. <strong>Confounding direction:</strong> Women who take supplements tend to be healthier‚Äîwhich would make folate look beneficial even if it weren't. But folate's effect persisted after adjusting for socioeconomic factors. When an effect survives adjustment for confounders that should bias toward it, the effect is likely real. The MRC RCT eventually confirmed 72% reduction‚Äîthe observational data had been right."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìâ", title: "Cen√°rio: A quest√£o dose-resposta",
        xp: 25,
        scenario: "A series of cohort studies shows alcohol consumption and liver cirrhosis. Results: 1-2 drinks/day (RR 1.2), 3-4 drinks/day (RR 2.1), 5-6 drinks/day (RR 4.5), 7+ drinks/day (RR 9.3). The gradient is consistent across studies and populations.",
        question: "Does this dose-response pattern support upgrading?",
        options: [
          { letter: "A", text: "N√£o ‚Äì todos os efeitos s√£o de estudos observacionais", correct: false },
          { letter: "B", text: "Yes‚Äîa consistent dose-response gradient across studies suggests causation", correct: true },
          { letter: "C", text: "Only if RR exceeds 2 at all dose levels", correct: false },
          { letter: "D", text: "Only if confounders show the same gradient", correct: false }
        ],
        feedback: {
          correct: "Correto! Um claro gradiente dose-resposta (1,2 ‚Üí 2,1 ‚Üí 4,5 ‚Üí 9,3) √© dif√≠cil de explicar por confus√£o. Um confundidor precisaria monitorar perfeitamente a ingest√£o de √°lcool em todos os n√≠veis em diversas popula√ß√µes. Este gradiente biol√≥gico apoia a causalidade e justifica a atualiza√ß√£o.",
          incorrect: "As rela√ß√µes dose-resposta fornecem fortes evid√™ncias de causalidade. Para que a confus√£o criasse esse padr√£o, algum fator desconhecido precisaria aumentar em propor√ß√£o perfeita √† ingest√£o de √°lcool, em todos os estudos e popula√ß√µes. Isso √© implaus√≠vel ‚Äì o gradiente aponta para causalidade."
        }
      }},
      { type: "story", theme: "green-bg", content: {
        label: "O paradoxo confuso", title: "When Bias Proves the Case",
        text: "Considere a observa√ß√£o de que os capacetes para motociclistas reduzem as mortes por ferimentos na cabe√ßa. Os cr√≠ticos poder√£o argumentar: ‚ÄúTalvez os utilizadores de capacete sejam condutores mais cautelosos‚Äù. Isso √© confuso ‚Äì e provavelmente √© verdade. Motoristas cautelosos provavelmente usam capacetes com mais frequ√™ncia.",
        followup: "But here's the paradox: if cautious driving confounds the relationship, it should bias <em>toward</em> helmets looking beneficial. Cautious drivers have fewer crashes and thus fewer head injuries. If helmets still show dramatic benefit <em>despite</em> this confounding working in their favor, the true effect might be even larger. When all plausible confounders bias in one direction and the effect persists (or is opposite), causation becomes more credible. This 'all plausible confounders' reasoning is GRADE's third upgrading criterion."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üîÑ", title: "Cen√°rio: A dire√ß√£o confusa",
        xp: 25,
        scenario: "Um estudo de registro mostra que uma nova t√©cnica cir√∫rgica reduz complica√ß√µes (RR 0,60). Voc√™ suspeita de confus√£o: pacientes mais saud√°veis ‚Äã‚Äãprovavelmente receber√£o a nova t√©cnica. Pacientes mais saud√°veis ‚Äã‚Äãteriam menos complica√ß√µes de qualquer maneira. Essa confus√£o deve influenciar os resultados no sentido de mostrar benef√≠cios.",
        question: "Does this confounding pattern support or undermine causation?",
        options: [
          { letter: "A", text: "Undermines‚Äîconfounding invalidates observational studies", correct: false },
          { letter: "B", text: "Supports‚Äîif benefit persists despite confounding that favors treatment, true benefit may exist", correct: true },
          { letter: "C", text: "Neutral‚Äîwe cannot determine confounding direction", correct: false },
          { letter: "D", text: "Undermines‚Äîwe need propensity score matching", correct: false }
        ],
        feedback: {
          correct: "Correct! If healthier patients get the new technique AND the technique still shows benefit, the true benefit might be real (or even underestimated). When confounding should bias toward benefit but benefit still appears after adjustment, that's evidence for causation. GRADE upgrades when 'all plausible confounders' would bias in the observed direction.",
          incorrect: "Think about the direction: healthy patient confounding should make the new technique look good. If the technique still shows benefit after adjusting for health status, the true effect is supported. The confounding direction helps interpret the finding."
        }
      }},
      { type: "concept", theme: "dark", content: {
        title: "Resumo dos crit√©rios de atualiza√ß√£o",
        subtitle: "Three paths to higher certainty",
        checkpoints: [
          { day: "LARGE", event: "RR > 2 or < 0.5 (upgrade 1); RR > 5 or < 0.2 (upgrade 2)" },
          { day: "DOSE", event: "Clear gradient between exposure and outcome" },
          { day: "CONFOUND", event: "All plausible confounders would reduce observed effect" }
        ]
      }},
      { type: "story", theme: "dark", content: {
        label: "A tempestade na tireoide", title: "When 96% Survival Speaks for Itself",
        text: "Before propylthiouracil (PTU), thyroid storm had <strong>nearly 100% mortality</strong>. With PTU, mortality dropped to around <strong>4%</strong>. No RCT was ever conducted‚Äîit would have required letting patients die in the control arm.",
        followup: "This is the paradigm case for large effect upgrading. A treatment that changes survival from ~0% to ~96% doesn't need an RCT. No confounder could explain turning certain death into reliable survival. The evidence quality was upgraded to HIGH despite being entirely observational. Some effects are simply too dramatic to doubt."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚ö†Ô∏è", title: "Cen√°rio: o efeito moderado",
        xp: 25,
        scenario: "Um estudo de coorte mostra que uma interven√ß√£o no estilo de vida reduz doen√ßas card√≠acas com RR 0,75 (redu√ß√£o relativa de 25%). O estudo √© grande, bem desenhado e com resultados consistentes. Um colega argumenta que isso merece uma atualiza√ß√£o para um grande efeito.",
        question: "Voc√™ deveria atualizar?",
        options: [
          { letter: "A", text: "Yes‚Äî25% reduction is clinically important", correct: false },
          { letter: "B", text: "No‚ÄîRR 0.75 is well within the range confounding can produce", correct: true },
          { letter: "C", text: "Yes‚Äîlarge sample size warrants upgrading", correct: false },
          { letter: "D", text: "Only if dose-response is also present", correct: false }
        ],
        feedback: {
          correct: "Correct! RR 0.75 is exactly the range where confounding thrives. The HRT disaster showed RR 0.50 for heart protection‚Äîentirely due to confounding. Large effect upgrading requires RR > 2 or < 0.5 (some use even stricter thresholds). Clinical importance ‚â† causal certainty.",
          incorrect: "RR 0.75 is modest and easily explained by healthy user bias, unmeasured confounders, or selection effects. HRT's observational RR of 0.50 was entirely confounded. Only effects so large that confounding is implausible (RR > 2 or < 0.5) qualify for upgrading."
        }
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Upgrading Criteria Checklist",
        items: [
          "Large effect: RR > 2 or < 0.5 (very large: > 5 or < 0.2)",
          "Dose-response: Clear gradient across exposure levels",
          "Confounding: All plausible confounders would reduce the effect",
          "Upgrading is rare‚Äîmost observational evidence remains LOW",
          "Multiple upgrading factors can be applied if clearly present"
        ]
      }},
      { type: "quiz", theme: "dark", content: {
        question: "Por que as evid√™ncias observacionais para tabagismo e c√¢ncer de pulm√£o alcan√ßaram ALTA certeza apesar de n√£o haver ECRs?",
        options: [
          { text: "Os estudos foram metodologicamente perfeitos", correct: false },
          { text: "Large effect (30x risk) + dose-response + no plausible confounders could explain it", correct: true },
          { text: "O mecanismo biol√≥gico foi bem compreendido", correct: false },
          { text: "V√°rios desenhos de estudo acordados", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Exactly. A 30-fold risk increase is beyond what confounding can explain. The clear dose-response (more cigarettes = more cancer) added evidence. And no unmeasured confounder has ever been found that could explain the effect. All three upgrading criteria were met.",
          incorrect: "The combination was powerful: an effect so large confounding couldn't explain it, a dose-response gradient supporting causation, and the direction of any conceivable confounding wouldn't diminish the finding. All three upgrading factors pushed the evidence to HIGH certainty."
        }
      }}
    ]
  },
  {
    id: 9, title: "Putting It Together", subtitle: "Real guideline decisions", xp: 200,
    slides: [
      { type: "title", theme: "dark", content: { title: "Putting It Together", subtitle: "Applying all five domains to real guideline decisions" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Apply all GRADE domains to complex real-world evidence",
          "Pratique a constru√ß√£o de resumos de evid√™ncias",
          "Make defensible certainty judgments",
          "Translate certainty to recommendation strength"
        ],
        tip: "Este m√≥dulo apresenta casos completos - voc√™ usar√° tudo o que aprendeu."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Caso 1: A controv√©rsia sobre estatinas", title: "Estatinas para preven√ß√£o prim√°ria",
        text: "In 2016, a Lancet review claimed statins for primary prevention were supported by <strong>'overwhelming evidence.'</strong> The meta-analysis showed 25% relative reduction in major vascular events. Industry-funded trials dominated. Patient advocates and independent researchers disagreed vehemently.",
        followup: "Let's assess this systematically. <strong>Risk of bias:</strong> Most trials industry-funded with concerns about selective reporting. <strong>Inconsistency:</strong> Effects varied by baseline risk‚Äîbenefit clear in high-risk, uncertain in low-risk. <strong>Indirectness:</strong> Many trials included patients with existing disease (secondary prevention). <strong>Imprecision:</strong> For low-risk primary prevention, confidence intervals crossed clinical thresholds. <strong>Publication bias:</strong> Industry sponsorship raised concerns about selective publication."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üíä", title: "Cen√°rio: avaliando a evid√™ncia de estatina",
        xp: 30,
        scenario: "For statins in LOW-RISK primary prevention (10-year CVD risk <10%), you have: industry-funded RCTs, some risk of bias concerns, heterogeneous results by risk level, outcomes measured may include secondary prevention patients, and modest absolute benefits (NNT ~200-500 to prevent one event over 5 years).",
        question: "Qual classifica√ß√£o de certeza √© mais apropriada para Redu√ß√£o de eventos cardiovasculares nesta popula√ß√£o?",
        options: [
          { letter: "A", text: "ALTO ‚Äî a meta-an√°lise √© grande e mostra benef√≠cios significativos", correct: false },
          { letter: "B", text: "MODERATE‚Äîdowngrade one level for indirectness (mixed populations)", correct: false },
          { letter: "C", text: "BAIXO‚Äîrebaixamento para indireta E imprecis√£o para esta popula√ß√£o espec√≠fica", correct: true },
          { letter: "D", text: "VERY LOW‚Äîmultiple serious concerns across domains", correct: false }
        ],
        feedback: {
          correct: "Correct! For low-risk primary prevention specifically: indirectness (trials mixed with higher-risk patients) and imprecision (modest absolute benefits, NNT 200-500) both warrant downgrading. The certainty differs by population‚Äîwhat's HIGH for secondary prevention may be LOW for low-risk primary prevention.",
          incorrect: "A pergunta pergunta especificamente sobre preven√ß√£o prim√°ria de BAIXO RISCO. A meta-an√°lise global inclui popula√ß√µes de maior risco onde o benef√≠cio √© mais claro. Para a popula√ß√£o espec√≠fica em quest√£o, tanto o car√°ter indireto como a imprecis√£o se aplicam. GRADE √© espec√≠fico da popula√ß√£o."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "Caso 2: A saga da hidroxicloroquina", title: "COVID-19 e certeza prematura",
        text: "In March 2020, a French study of <strong>36 patients</strong> claimed hydroxychloroquine cleared COVID-19 viral load. The study was open-label, non-randomized, with selective exclusion of patients who died or went to ICU. Despite this, world leaders promoted it and millions of doses were prescribed.",
        followup: "Systematic GRADE assessment would have revealed: <strong>Risk of bias:</strong> CRITICAL (non-randomized, open-label, selective exclusion). <strong>Imprecision:</strong> SERIOUS (36 patients, 6 in treatment arm). <strong>Indirectness:</strong> SERIOUS (viral load, not clinical outcomes). Certainty: <strong>VERY LOW</strong>. Subsequent RCTs (RECOVERY, WHO Solidarity) showed no benefit. The pandemic revealed what happens when certainty assessment is bypassed."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ü¶†", title: "Cen√°rio: avaliando evid√™ncias de pandemia",
        xp: 30,
        scenario: "Um novo v√≠rus respirat√≥rio emerge. Um estudo unic√™ntrico com 80 pacientes (n√£o randomizado, aberto) mostra que um medicamento reaproveitado reduz a interna√ß√£o na UTI de 25% para 12%. Os resultados s√£o promovidos como 'promissores' e geram uma enorme demanda p√∫blica.",
        question: "Como essas evid√™ncias devem ser avaliadas e comunicadas?",
        options: [
          { letter: "A", text: "MODERADO - o tamanho do efeito √© grande e clinicamente significativo", correct: false },
          { letter: "B", text: "BAIXO - estudo observacional com s√©rias limita√ß√µes", correct: false },
          { letter: "C", text: "VERY LOW‚Äîcritical risk of bias, serious imprecision; communicate uncertainty clearly", correct: true },
          { letter: "D", text: "Cannot rate‚Äîmore studies needed before any assessment", correct: false }
        ],
        feedback: {
          correct: "Correct! Non-randomized, open-label, single-center, n=80: VERY LOW certainty. The effect might be real, might be selection bias, might be confounding. Communicating this uncertainty‚Äînot dismissing the evidence, but properly contextualizing it‚Äîis essential for informed decision-making.",
          incorrect: "Este cen√°rio reflete hidroxicloroquina. O risco cr√≠tico de vi√©s (n√£o randomizado, aberto) mais imprecis√£o grave (80 pacientes) produz uma certeza MUITO BAIXA. Isso n√£o significa 'ignorar' - significa comunicar a profunda incerteza enquanto se aguarda melhores evid√™ncias."
        }
      }},
      { type: "story", theme: "green-bg", content: {
        label: "Case 3: The Insulin Pump Victory", title: "When Certainty Builds Slowly",
        text: "A infus√£o subcut√¢nea cont√≠nua de insulina (terapia com bomba) para diabetes tipo 1 acumulou evid√™ncias ao longo de d√©cadas. Os primeiros testes foram pequenos. Os resultados variaram. Nenhum ensaio foi definitivo. Mas com o tempo, o mosaico se formou.",
        followup: "By 2010, meta-analyses showed: consistent HbA1c improvement (~0.3%), reduced severe hypoglycemia, improved quality of life. <strong>Risk of bias:</strong> Some concerns but improving over time. <strong>Inconsistency:</strong> Low for HbA1c, moderate for hypoglycemia (likely explainable by patient selection). <strong>Indirectness:</strong> None‚Äîdirect outcomes in target population. <strong>Imprecision:</strong> Resolved with cumulative trials. <strong>Publication bias:</strong> Low concern with trials in multiple settings. Final rating: <strong>MODERATE to HIGH</strong> for HbA1c improvement, with appropriate nuance for other outcomes."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìã", title: "Cen√°rio: A base de evid√™ncias em evolu√ß√£o",
        xp: 25,
        scenario: "You're updating a guideline. Five years ago, certainty was LOW for a treatment. Since then: 3 new large RCTs with low risk of bias, consistent results (I¬≤=18%), direct population and outcomes, total events now exceed OIS, no evidence of publication bias.",
        question: "What certainty rating is now appropriate?",
        options: [
          { letter: "A", text: "Remains LOW‚Äîinitial rating shouldn't change dramatically", correct: false },
          { letter: "B", text: "MODERATE‚Äînew evidence improves but doesn't transform certainty", correct: false },
          { letter: "C", text: "HIGH‚Äînew RCTs with no serious concerns across domains", correct: true },
          { letter: "D", text: "Requires independent replication before upgrading", correct: false }
        ],
        feedback: {
          correct: "Correct! GRADE ratings should evolve as evidence evolves. Starting HIGH (RCTs), no downgrading needed: low risk of bias, consistent (I¬≤=18%), direct outcomes, adequate precision (exceeds OIS), no publication bias concern. The evidence now supports HIGH certainty.",
          incorrect: "GRADE √© uma estrutura viva. √Ä medida que as evid√™ncias se acumulam e abordam preocupa√ß√µes anteriores, a certeza deve ser reavaliada. Tr√™s grandes ECRs de baixo vi√©s com resultados consistentes abordando todos os dom√≠nios podem aumentar absolutamente a certeza de BAIXO para ALTO."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Case 4: The Arthroscopy Lesson Revisited", title: "When Guidelines Persist Despite Evidence",
        text: "Em 2008, dois ECRs de cirurgia simulada mostraram que a artroscopia do joelho para osteoartrite n√£o era melhor que o placebo. A evid√™ncia foi de ALTA certeza ‚Äì ensaios cl√≠nicos randomizados bem elaborados, resultados consistentes, resultados diretos. No entanto, as diretrizes levaram anos para serem alteradas e o procedimento continuou.",
        followup: "This reveals GRADE's limitation: certainty ratings inform decisions but don't make them. Surgeons argued: 'My patients improve.' Patients wanted the procedure. Systems had invested in it. A HIGH certainty of 'no benefit' should have ended the practice‚Äîbut implementation requires more than evidence rating. GRADE tells us what the evidence says; behavior change requires understanding why evidence gets ignored."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üî¨", title: "Cen√°rio: A lacuna entre evid√™ncias e pr√°ticas",
        xp: 25,
        scenario: "Seu painel de diretrizes classifica as evid√™ncias como de ALTA certeza de que um procedimento comum n√£o √© melhor que o placebo. O procedimento √© lucrativo, amplamente realizado e os pacientes relatam satisfa√ß√£o. Os membros do painel discordam sobre a for√ßa da recomenda√ß√£o.",
        question: "What recommendation strength is appropriate given HIGH certainty of no benefit?",
        options: [
          { letter: "A", text: "Strong recommendation AGAINST‚Äîhigh certainty of no benefit demands strong action", correct: true },
          { letter: "B", text: "Conditional recommendation against‚Äîpatient preferences matter", correct: false },
          { letter: "C", text: "No recommendation‚Äîpractice patterns should determine guidelines", correct: false },
          { letter: "D", text: "Conditional recommendation for‚Äîpatients report benefit", correct: false }
        ],
        feedback: {
          correct: "Correct! HIGH certainty that a procedure provides no benefit over placebo justifies a STRONG recommendation against. Patient-reported benefit in unblinded settings is placebo effect. Resource use for ineffective treatments has opportunity costs. High certainty + unfavorable balance = strong recommendation.",
          incorrect: "Quando a certeza √© ALTA e o equil√≠brio √© claramente desfavor√°vel (sem benef√≠cio, riscos cir√∫rgicos, custos), o GRADE apoia uma recomenda√ß√£o forte. A satisfa√ß√£o do paciente com o placebo n√£o justifica o uso continuado de procedimentos invasivos. Evid√™ncias fortes devem gerar recomenda√ß√µes fortes."
        }
      }},
      { type: "concept", theme: "dark", content: {
        title: "Da Certeza √†s Recomenda√ß√µes",
        subtitle: "A qualidade da evid√™ncia √© apenas parte da equa√ß√£o",
        text: "GRADE separates certainty of evidence from strength of recommendations. A recommendation considers:<br><br>‚Ä¢ Certainty of evidence<br>‚Ä¢ Balance of benefits vs. harms<br>‚Ä¢ Patient values and preferences<br>‚Ä¢ Resource use and feasibility",
        highlight: "Even LOW certainty evidence can support a STRONG recommendation (e.g., parachutes) if benefits clearly outweigh harms."
      }},
      { type: "story", theme: "dark", content: {
        label: "Caso 5: O Limiar de Transfus√£o", title: "When Less Is More",
        text: "For decades, blood transfusion thresholds were set at hemoglobin <10 g/dL‚Äîthe '10/30 rule.' The practice seemed logical: more blood should be better for anemic patients. Then came the RCTs.",
        followup: "The TRICC trial (1999) and subsequent studies showed <strong>restrictive transfusion (Hb <7 g/dL)</strong> was as safe or safer than liberal transfusion in most patients. The evidence accumulated: <strong>Risk of bias:</strong> Low in major trials. <strong>Inconsistency:</strong> Low across settings. <strong>Indirectness:</strong> Some subgroups less studied. <strong>Imprecision:</strong> Resolved with multiple trials. <strong>Publication bias:</strong> Unlikely given consistent direction. Certainty: <strong>MODERATE to HIGH</strong> for most populations. Guidelines changed. A practice that had seemed obviously beneficial was actually harmful."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ü©∏", title: "Cen√°rio: O Restritivo Estrat√©gia",
        xp: 25,
        scenario: "V√°rios ensaios cl√≠nicos randomizados mostram que a transfus√£o de sangue restritiva √© t√£o segura quanto a transfus√£o liberal, com menor mortalidade em alguns subgrupos. No entanto, para pacientes com s√≠ndrome coronariana aguda, existe apenas um pequeno ECR com amplos intervalos de confian√ßa que cruzam limites clinicamente importantes.",
        question: "How should certainty differ between general hospital patients and ACS patients?",
        options: [
          { letter: "A", text: "Mesma certeza ‚Äì a evid√™ncia geral se aplica a todos os pacientes", correct: false },
          { letter: "B", text: "Menor para SCA ‚Äì imprecis√£o e indireta requerem avalia√ß√£o separada", correct: true },
          { letter: "C", text: "Maior para SCA‚Äîeles t√™m mais a perder com complica√ß√µes transfusionais", correct: false },
          { letter: "D", text: "N√£o √© poss√≠vel avaliar SCA‚Äîevid√™ncias insuficientes para qualquer conclus√£o", correct: false }
        ],
        feedback: {
          correct: "Correto! Pacientes com SCA t√™m raz√µes biol√≥gicas para diferentes respostas (demanda mioc√°rdica de oxig√™nio). Um pequeno ECR impreciso nesta popula√ß√£o significa que o car√°ter indireto (extrapolando de pacientes em geral) ou a imprecis√£o (evid√™ncia direta de SCA), ambos garantem menor certeza. GRADE √© espec√≠fico da popula√ß√£o.",
          incorrect: "GRADE requer avalia√ß√£o de certeza para cada popula√ß√£o espec√≠fica. Os pacientes com SCA podem responder de forma diferente dos pacientes do hospital geral. Um pequeno estudo impreciso diretamente em pacientes com SCA n√£o fornece a mesma certeza que a base de evid√™ncias mais ampla para outras popula√ß√µes."
        }
      }},
      { type: "quiz", theme: "dark", content: {
        question: "Qual √© a li√ß√£o mais importante da experi√™ncia da hidroxicloroquina COVID-19?",
        options: [
          { text: "Estudos observacionais s√£o sempre n√£o confi√°veis", correct: false },
          { text: "Proper GRADE assessment should precede clinical adoption and policy", correct: true },
          { text: "Repurposed drugs don't work for new diseases", correct: false },
          { text: "A m√≠dia n√£o deve noticiar informa√ß√µes m√©dicas estudos", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Exatamente. Um estudo aberto, n√£o randomizado e com 36 pacientes, com exclus√µes seletivas, teve uma certeza MUITO BAIXA em qualquer avalia√ß√£o GRADE. A avalia√ß√£o sistem√°tica da certeza antes da ado√ß√£o teria evitado o uso generalizado de um tratamento ineficaz e mantido a confian√ßa do p√∫blico.",
          incorrect: "A li√ß√£o n√£o √© que pequenos estudos s√£o in√∫teis ‚Äì √© que eles precisam de uma avalia√ß√£o adequada da certeza. Uma avalia√ß√£o rigorosa do GRADE teria rotulado essa certeza como MUITO BAIXA imediatamente. A avalia√ß√£o sistem√°tica deve preceder a ado√ß√£o cl√≠nica, especialmente durante crises quando a press√£o √© mais alta."
        }
      }}
    ]
  },
  {
    id: 10, title: "Final Assessment", subtitle: "Teste seu dom√≠nio", xp: 250,
    slides: [
      { type: "title", theme: "dark", content: { title: "Final Assessment", subtitle: "Demonstrate your mastery of GRADE certainty assessment" }},
      { type: "concept", theme: "dark", content: {
        title: "O Desafio Final",
        subtitle: "Apply everything you've learned",
        text: "Este m√≥dulo apresenta cen√°rios complexos que exigem avalia√ß√£o GRADE integrada. Voc√™ precisar√° considerar v√°rios dom√≠nios simultaneamente e fazer julgamentos diferenciados.",
        highlight: "Tente 80% de precis√£o para ganhar o selo GRADE Master!"
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìä", title: "Challenge 1: The New Cancer Drug",
        xp: 35,
        scenario: "A new cancer drug shows median survival improvement from 11 to 14 months in a single industry-funded RCT (n=600). Primary outcome was changed mid-trial from overall survival to progression-free survival. Three of seven pre-specified secondary outcomes were not reported. The survival benefit was a post-hoc analysis.",
        question: "What certainty rating is appropriate for overall survival benefit?",
        options: [
          { letter: "A", text: "HIGH‚ÄîRCT showing survival benefit", correct: false },
          { letter: "B", text: "MODERATE‚Äîsingle trial but clinically meaningful", correct: false },
          { letter: "C", text: "LOW‚Äîdowngrade for risk of bias (outcome switching, selective reporting)", correct: true },
          { letter: "D", text: "VERY LOW‚Äîmultiple serious concerns", correct: false }
        ],
        feedback: {
          correct: "Correct! Key risk of bias concerns: (1) primary outcome changed mid-trial, (2) unreported secondary outcomes, (3) survival benefit was post-hoc. Each suggests selective reporting. Starting HIGH, downgrade one or two levels for serious risk of bias. Industry funding adds concern but isn't sufficient alone for downgrading.",
          incorrect: "The trial shows classic selective reporting: changing primary endpoint, hiding unfavorable secondary outcomes, promoting post-hoc survival analysis. These risk of bias concerns require downgrading even when the finding itself is statistically significant."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üîç", title: "Desafio 2: O quebra-cabe√ßa de meta-an√°lise",
        xp: 35,
        scenario: "A meta-analysis of 20 RCTs (n=15,000) shows significant mortality reduction (RR 0.85, 95% CI 0.76-0.95). However: I¬≤=68%, prediction interval 0.62-1.15, funnel plot shows slight asymmetry, 4 trials registered but never published.",
        question: "Which domains require downgrading and by how much?",
        options: [
          { letter: "A", text: "Inconsistency (‚àí1), publication bias (‚àí1): HIGH ‚Üí LOW", correct: true },
          { letter: "B", text: "Imprecision only (‚àí1): HIGH ‚Üí MODERATE", correct: false },
          { letter: "C", text: "Inconsistency (‚àí2): HIGH ‚Üí LOW", correct: false },
          { letter: "D", text: "Publication bias only (‚àí1): HIGH ‚Üí MODERATE", correct: false }
        ],
        feedback: {
          correct: "Correct! Inconsistency: I¬≤=68% with prediction interval crossing 1.0 (could show harm) warrants one downgrade. Publication bias: 4 registered but unpublished trials plus funnel asymmetry warrants one downgrade. Two domains = two downgrades = HIGH ‚Üí LOW.",
          incorrect: "O intervalo de previs√£o (0,62-1,15) ultrapassa 1,0 - o pr√≥ximo estudo pode mostrar danos. Isso √© uma inconsist√™ncia grave. A assimetria do funil mais 4 ensaios registrados n√£o publicados √© evid√™ncia direta de vi√©s de publica√ß√£o. Ambos os dom√≠nios merecem rebaixamento."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üíâ", title: "Desafio 3: A efic√°cia da vacina",
        xp: 35,
        scenario: "A vaccine trial (n=40,000) shows 95% efficacy against symptomatic disease (RR 0.05, 95% CI 0.03-0.08). Low risk of bias, consistent subgroup results, direct outcome. However, follow-up is only 3 months, and durability of protection is unknown.",
        question: "How should certainty be rated for short-term vs. long-term efficacy?",
        options: [
          { letter: "A", text: "HIGH for both‚Äîlarge, well-conducted trial", correct: false },
          { letter: "B", text: "HIGH for short-term; VERY LOW for long-term (no data)", correct: false },
          { letter: "C", text: "HIGH for short-term efficacy; LOW for 12-month efficacy (indirect/imprecise)", correct: true },
          { letter: "D", text: "MODERATE for both‚Äîduration uncertainty affects all conclusions", correct: false }
        ],
        feedback: {
          correct: "Correct! Short-term efficacy: large RCT, low bias, precise, direct = HIGH. Long-term efficacy: either indirect (extrapolating from 3 months) or imprecise (no data). GRADE is outcome-specific‚Äîdifferent time horizons may have different certainty ratings.",
          incorrect: "GRADE avalia a certeza para resultados espec√≠ficos. Os dados de tr√™s meses apoiam diretamente a efic√°cia de 3 meses (ALTA). A efic√°cia em doze meses requer extrapola√ß√£o (indiretividade) ou n√£o possui dados diretos (imprecis√£o). O mesmo ensaio apoia diferentes certezas para diferentes quest√µes."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚öñÔ∏è", title: "Desafio 4: A atualiza√ß√£o observacional",
        xp: 35,
        scenario: "Cohort studies show a procedure reduces mortality from 95% to 15% (RR 0.16). No RCTs exist because the natural history (95% death) makes randomization unethical. Dose-response is present: earlier intervention shows better outcomes. All plausible confounders would make patients receiving intervention sicker (selection of more severe cases).",
        question: "Essa evid√™ncia observacional deve ser atualizada, e em que n√≠vel?",
        options: [
          { letter: "A", text: "No upgrade‚Äîobservational evidence stays LOW", correct: false },
          { letter: "B", text: "Upgrade to MODERATE‚Äîone upgrading factor (large effect)", correct: false },
          { letter: "C", text: "Upgrade to HIGH‚Äîall three upgrading factors clearly present", correct: true },
          { letter: "D", text: "Upgrade to MODERATE‚Äîobservational can never reach HIGH", correct: false }
        ],
        feedback: {
          correct: "Correct! All three upgrading factors: (1) Large effect‚ÄîRR 0.16 (84% relative reduction from 95% to 15%). (2) Dose-response‚Äîearlier = better. (3) Confounding direction‚Äîsicker patients receive intervention, which would bias AGAINST benefit if anything. Multiple upgrading factors can raise observational evidence to HIGH.",
          incorrect: "Isso atende a todos os tr√™s crit√©rios de atualiza√ß√£o. O tamanho do efeito (RR 0,16) √© muito grande ‚Äì 95% a 15% de mortalidade. Dose-resposta presente. E a confus√£o √© OPOSTA ao efeito observado (pacientes mais doentes fazem o procedimento). As evid√™ncias observacionais podem atingir ALTA certeza quando todos os crit√©rios s√£o claramente atendidos."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üéØ", title: "Desafio 5: O resultado composto",
        xp: 35,
        scenario: "An RCT shows significant reduction in 'major adverse cardiovascular events' (MACE: CV death, MI, stroke). However, decomposition reveals: CV death RR 1.02 (95% CI 0.85-1.22), MI RR 0.82 (0.72-0.94), Stroke RR 0.95 (0.80-1.13). The MACE benefit is driven entirely by MI.",
        question: "How should certainty differ for MACE vs. individual components?",
        options: [
          { letter: "A", text: "Same certainty‚ÄîMACE is the primary outcome", correct: false },
          { letter: "B", text: "MACE HIGH; CV death/stroke may be rated MODERATE (imprecision)", correct: false },
          { letter: "C", text: "MI HIGH; CV death/stroke LOW (CI includes substantial harm/benefit); MACE MODERATE (driven by MI)", correct: true },
          { letter: "D", text: "Todos os componentes ALTOS - eles s√£o do mesmo ECR bem conduzido", correct: false }
        ],
        feedback: {
          correct: "Correct! GRADE is outcome-specific. MI evidence is precise (0.72-0.94 excludes 1.0). CV death and stroke CIs are wide and cross 1.0‚Äîwe can't exclude no effect or harm. MACE driven entirely by MI means the composite obscures component-specific uncertainty. Different outcomes warrant different ratings even from the same trial.",
          incorrect: "Os resultados compostos podem mascarar a incerteza espec√≠fica do componente. O ECR mostra clara redu√ß√£o de IM, mas incerteza sobre morte CV e acidente vascular cerebral. Pacientes e m√©dicos precisam saber se o medicamento previne mortes ou apenas eventos n√£o fatais. GRADE classifica cada resultado separadamente."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìâ", title: "Desafio 6: A descoberta fr√°gil",
        xp: 35,
        scenario: "A meta-analysis of 5 small RCTs (total n=800, 48 events) shows statistically significant mortality benefit (RR 0.55, 95% CI 0.32-0.95, p=0.03). The fragility index is 2. A single large RCT (n=3,000) is underway.",
        question: "What certainty rating is appropriate while awaiting the large trial?",
        options: [
          { letter: "A", text: "HIGH‚Äîstatistically significant benefit from RCTs", correct: false },
          { letter: "B", text: "MODERATE‚Äîsome imprecision but consistent direction", correct: false },
          { letter: "C", text: "LOW‚Äîserious imprecision (48 events, fragility index 2, below OIS)", correct: true },
          { letter: "D", text: "N√£o √© poss√≠vel avaliar - aguarde o grande teste", correct: false }
        ],
        feedback: {
          correct: "Correct! 48 events is far below typical OIS (200-400 for mortality). Fragility index of 2 means 2 different outcomes would flip the result. The CI is wide (0.32-0.95). This is classic imprecision requiring downgrade. We can make provisional conclusions while acknowledging the large trial may change everything.",
          incorrect: "Statistical significance doesn't guarantee precision. The fragility index of 2 means the 'significant' result is extremely unstable. 48 events is grossly underpowered for mortality conclusions. GRADE requires downgrading for imprecision‚Äîwe should be honest about uncertainty while awaiting better data."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üß¨", title: "Desafio 7: O resultado substituto",
        xp: 35,
        scenario: "A drug dramatically improves bone mineral density (+8% annually). Observational data suggest each 1% density improvement correlates with 5% fracture reduction. No fracture outcome trials have been conducted. The drug class has previously produced agents where density improved but fractures increased.",
        question: "What certainty applies to fracture prevention?",
        options: [
          { letter: "A", text: "MODERATE‚Äîstrong surrogate relationship", correct: false },
          { letter: "B", text: "LOW‚Äîindirect evidence, but plausible mechanism", correct: false },
          { letter: "C", text: "VERY LOW‚Äîserious indirectness (surrogate only) PLUS known discordance in drug class", correct: true },
          { letter: "D", text: "Cannot rate until fracture trials complete", correct: false }
        ],
        feedback: {
          correct: "Correct! Surrogate outcomes require downgrading for indirectness. But here there's added concern: the drug class has precedent for density-fracture discordance (like sodium fluoride). This history of surrogate-outcome discordance in the same class warrants serious downgrading. Starting LOW (observational), downgrade further for known class discordance.",
          incorrect: "O caso do fluoreto de s√≥dio (densidade aumentada, fraturas up) √© diretamente relevante ‚Äì mesma classe de medicamentos com discord√¢ncia conhecida de resultados substitutos. Quando uma classe de medicamentos demonstra que o substituto pode mover-se na dire√ß√£o oposta aos resultados, os dados substitutos de um novo medicamento nessa classe s√£o profundamente incertos."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üè•", title: "Desafio 8: A evid√™ncia em n√≠vel de sistema",
        xp: 35,
        scenario: "Um ECR de cluster escalonado mostra que um protocolo hospitalar reduz a mortalidade em 30 dias (OR 0,75, IC 95% 0,62-0,91). Participaram vinte hospitais. No entanto, a interven√ß√£o foi implementada de forma diferente entre os locais, os resultados foram avaliados de forma n√£o cega e 5 hospitais desistiram no meio do ensaio.",
        question: "Quais dom√≠nios GRADE s√£o afetados por essas caracter√≠sticas metodol√≥gicas?",
        options: [
          { letter: "A", text: "Risk of bias only‚Äîother domains unaffected", correct: false },
          { letter: "B", text: "Risk of bias (unblinded, attrition) + inconsistency (implementation variation)", correct: true },
          { letter: "C", text: "Imprecision only‚Äî20 hospitals may be insufficient", correct: false },
          { letter: "D", text: "Indirectness‚Äîcluster trials don't apply to individual patients", correct: false }
        ],
        feedback: {
          correct: "Correct! Risk of bias: unblinded outcome assessment introduces detection bias; 5 hospital withdrawals are attrition bias. Inconsistency: variable implementation across sites may cause heterogeneity (different hospitals implementing different versions). Both domains warrant scrutiny.",
          incorrect: "A avalia√ß√£o n√£o cega e o atrito (5 hospitais abandonam o estudo) s√£o preocupa√ß√µes cl√°ssicas de risco de vi√©s. A implementa√ß√£o vari√°vel √© uma preocupa√ß√£o de inconsist√™ncia - se os hospitais forem implementados de forma diferente, a 'interven√ß√£o' n√£o √© uniforme e os resultados podem variar de acordo com a fidelidade da implementa√ß√£o."
        }
      }},
      { type: "stats", theme: "dark", content: {
        title: "GRADE in Numbers",
        stats: [
          { value: "4", label: "Certainty levels" },
          { value: "5", label: "Downgrading domains" },
          { value: "3", label: "Upgrading factors" },
          { value: "‚àû", label: "Lives protected by rigorous assessment" }
        ],
        caption: "Systematic certainty assessment protects patients from overconfident medicine."
      }},
      { type: "refrain", theme: "black", content: { text: "A certeza n√£o √© sobre quanta evid√™ncia existe. √â sobre o quanto devemos confiar nisso." }},
      { type: "quiz", theme: "dark", content: {
        question: "Qual √© a vis√£o fundamental que o GRADE fornece para a medicina baseada em evid√™ncias?",
        options: [
          { text: "Estudos maiores s√£o sempre melhores", correct: false },
          { text: "Os ECRs s√£o os √∫nicos v√°lidos evid√™ncias", correct: false },
          { text: "A certeza deve ser avaliada sistematicamente, com fundamenta√ß√£o transparente para cada dom√≠nio", correct: true },
          { text: "Meta-analyses provide definitive answers", correct: false }
        ],
        xp: 25,
        feedback: {
          correct: "Exactly. GRADE transforms implicit judgments into explicit, transparent assessments. By systematically considering risk of bias, inconsistency, indirectness, imprecision, and publication bias‚Äîand documenting reasoning‚ÄîGRADE makes certainty assessment reproducible and debatable. This transparency is its core contribution.",
          incorrect: "A contribui√ß√£o fundamental do GRADE √© a transpar√™ncia estruturada. Em vez de r√≥tulos de qualidade vagos, requer uma avalia√ß√£o sistem√°tica de dom√≠nios espec√≠ficos com fundamenta√ß√£o expl√≠cita. Isto torna os julgamentos de certeza reproduz√≠veis, discut√≠veis e melhor√°veis ‚Äã‚Äã√† medida que as evid√™ncias se acumulam."
        }
      }}
    ]
  }
];

// ===== NAVIGATION STATE =====
let currentModule = 0;
let currentSlide = 0;
let consecutiveCorrect = gameState.consecutiveCorrect || 0;

// ===== SAVE/LOAD =====
function saveGame() {
  safeSetStorage('gradeGame_v1', gameState);
}

function resetProgress() {
  if (confirm('Reset all progress and achievements?')) {
    gameState = { ...DEFAULT_STATE, answeredQuestions: {}, badges: [], completedModules: [] };
    saveGame();
    currentModule = 0;
    currentSlide = 0;
    renderAll();
  }
}

// ===== COURSE PROGRESS =====
function updateCourseProgress() {
  const totalModules = MODULES.length;
  const completedCount = gameState.completedModules.length;
  const pct = Math.round((completedCount / totalModules) * 100);
  const fillEl = document.getElementById('courseProgressFill');
  const pctEl = document.getElementById('courseProgressPct');
  if (fillEl) fillEl.style.width = pct + '%';
  if (pctEl) pctEl.textContent = pct + '%';
}

// ===== XP & LEVELING =====
function addXP(amount) {
  gameState.xp += amount;
  checkLevelUp();
  saveGame();
  updateStatsDisplay();
  showXPPopup(amount);
}

function checkLevelUp() {
  for (let i = LEVELS.length - 1; i >= 0; i--) {
    if (gameState.xp >= LEVELS[i].xp && gameState.level < LEVELS[i].level) {
      gameState.level = LEVELS[i].level;
      showLevelUp(LEVELS[i]);
      break;
    }
  }
}

function showXPPopup(amount) {
  const popup = document.getElementById('xpPopup');
  document.getElementById('xpAmount').textContent = `+${amount}`;
  popup.classList.add('show');
  setTimeout(() => popup.classList.remove('show'), 1500);
}

function showLevelUp(levelData) {
  triggerConfetti();
}

// ===== BADGES =====
function awardBadge(badgeId) {
  if (gameState.badges.includes(badgeId)) return;
  gameState.badges.push(badgeId);
  saveGame();
  const badge = BADGES.find(b => b.id === badgeId);
  if (badge) showBadgeModal(badge);
  updateBadges();
}

function showBadgeDetails(badgeId) {
  const badge = BADGES.find(b => b.id === badgeId);
  if (badge) showBadgeModal(badge);
}

let _badgeModalTrapHandler = null;

function showBadgeModal(badge) {
  const modal = document.getElementById('badgeModal');
  document.getElementById('badgeModalIcon').textContent = badge.icon;
  document.getElementById('badgeModalTitle').textContent = badge.name;
  document.getElementById('badgeModalDesc').textContent = badge.desc;
  modal.classList.add('show');
  triggerConfetti();

  // Focus trap for accessibility
  const focusableElements = modal.querySelectorAll('button, [tabindex]:not([tabindex="-1"])');
  if (focusableElements.length > 0) {
    focusableElements[0].focus();
  }

  // Remove any previous handler before adding a new one
  if (_badgeModalTrapHandler) {
    modal.removeEventListener('keydown', _badgeModalTrapHandler);
  }

  _badgeModalTrapHandler = function(e) {
    if (e.key === 'Escape') {
      closeBadgeModal();
      return;
    }
    if (e.key === 'Tab') {
      const firstFocusable = focusableElements[0];
      const lastFocusable = focusableElements[focusableElements.length - 1];
      if (e.shiftKey && document.activeElement === firstFocusable) {
        e.preventDefault();
        lastFocusable.focus();
      } else if (!e.shiftKey && document.activeElement === lastFocusable) {
        e.preventDefault();
        firstFocusable.focus();
      }
    }
  };
  modal.addEventListener('keydown', _badgeModalTrapHandler);
}

function closeBadgeModal() {
  const modal = document.getElementById('badgeModal');
  if (_badgeModalTrapHandler) {
    modal.removeEventListener('keydown', _badgeModalTrapHandler);
    _badgeModalTrapHandler = null;
  }
  modal.classList.remove('show');
}

// ===== STREAK =====
function updateStreak() {
  const today = new Date().toDateString();
  if (gameState.lastActive !== today) {
    const yesterday = new Date(Date.now() - 86400000).toDateString();
    if (gameState.lastActive === yesterday) {
      gameState.streak++;
      if (gameState.streak >= 3) awardBadge('streak_3');
      if (gameState.streak >= 7) awardBadge('streak_7');
    } else if (gameState.lastActive) {
      gameState.streak = 1;
    } else {
      gameState.streak = 1;
    }
    gameState.lastActive = today;
    saveGame();
  }
}

// ===== CONFETTI =====
function triggerConfetti() {
  if (window.matchMedia('(prefers-reduced-motion: reduce)').matches) return;
  const container = document.getElementById('confettiContainer');
  const colors = ['#D4AF37', '#22c55e', '#3b82f6', '#f59e0b', '#ef4444', '#7c3aed'];
  for (let i = 0; i < 50; i++) {
    const confetti = document.createElement('div');
    confetti.className = 'confetti';
    confetti.style.left = Math.random() * 100 + '%';
    confetti.style.background = colors[Math.floor(Math.random() * colors.length)];
    confetti.style.animationDelay = Math.random() * 0.5 + 's';
    container.appendChild(confetti);
    setTimeout(() => confetti.remove(), 3500);
  }
}

// ===== COMBO =====
function updateComboDisplay() {
  const comboEl = document.getElementById('comboDisplay');
  const countEl = document.getElementById('comboCount');
  if (consecutiveCorrect >= 2) {
    countEl.textContent = consecutiveCorrect;
    comboEl.classList.add('show');
  } else {
    comboEl.classList.remove('show');
  }
}

// ===== MOBILE SIDEBAR =====
function toggleSidebar() {
  document.querySelector('.sidebar').classList.toggle('open');
  document.getElementById('sidebarOverlay').classList.toggle('show');
  var btn = document.querySelector('.sidebar-toggle, .hamburger, .mobile-menu-btn'); if (btn) btn.setAttribute('aria-expanded', btn.getAttribute('aria-expanded') === 'true' ? 'false' : 'true');
}

// ===== RENDER =====
function renderAll() {
  updateStreak();
  renderSidebar();
  renderSlides();
  updateStatsDisplay();
  updateBadges();
  updateCourseProgress();
}

function updateStatsDisplay() {
  const levelData = LEVELS.find(l => l.level === gameState.level) || LEVELS[0];
  const nextLevel = LEVELS.find(l => l.level === gameState.level + 1);

  document.getElementById('levelIcon').textContent = levelData.icon;
  document.getElementById('levelTitle').textContent = levelData.title;
  document.getElementById('levelNum').textContent = gameState.level;

  const currentXP = gameState.xp - levelData.xp;
  const neededXP = nextLevel ? (nextLevel.xp - levelData.xp) : 500;
  const pct = Math.min(100, (currentXP / neededXP) * 100);

  document.getElementById('xpFill').style.width = pct + '%';
  document.getElementById('xpCurrent').textContent = currentXP;
  document.getElementById('xpNeeded').textContent = neededXP;

  document.getElementById('correctCount').textContent = gameState.correctAnswers;
  document.getElementById('decisionCount').textContent = gameState.decisionsCompleted;
  document.getElementById('gradesCount').textContent = gameState.gradesAssigned || 0;
  document.getElementById('streakCount').textContent = gameState.streak;

  const streakEl = document.getElementById('streakDisplay');
  streakEl.classList.toggle('active', gameState.streak > 0);
}

function updateBadges() {
  const grid = document.getElementById('badgesGrid');
  grid.innerHTML = BADGES.map(b => {
    const earned = gameState.badges.includes(b.id);
    return `<button class="badge-item ${earned ? 'earned' : ''}" type="button" ${earned ? `onclick="showBadgeDetails('${b.id}')"` : ''} aria-label="${b.name}: ${b.desc}" title="${b.name}: ${b.desc}" style="min-width:44px;min-height:44px">${b.icon}</button>`;
  }).join('');
}

function renderSidebar() {
  const list = document.getElementById('moduleList');
  list.innerHTML = MODULES.map((mod, i) => {
    const completed = gameState.completedModules.includes(mod.id);
    const locked = i > 0 && !gameState.completedModules.includes(MODULES[i-1].id);
    const estMins = Math.round(mod.slides.length * 1.5);
    return `
      <div class="module-item ${i === currentModule ? 'active' : ''} ${completed ? 'completed' : ''} ${locked ? 'locked' : ''}"
           onclick="${locked ? '' : `goToModule(${i})`}"
           tabindex="${locked ? -1 : 0}"
           role="button"
           aria-disabled="${locked ? 'true' : 'false'}">
        <div class="module-number">${completed ? '‚úì' : (locked ? 'üîí' : mod.id)}</div>
        <div class="module-info">
          <div class="module-title">${mod.title}</div>
          <div class="module-subtitle">${mod.subtitle}</div>
          <div class="module-xp">+${mod.xp} XP</div>
          <div class="module-time">‚è±Ô∏è ~${estMins} min</div>
        </div>
      </div>
    `;
  }).join('');
}

function renderSlides() {
  const container = document.getElementById('slidesContainer');
  container.innerHTML = MODULES.map((mod, mi) => {
    const progressPct = ((currentSlide + 1) / mod.slides.length) * 100;
    return `
    <div class="module-slides ${mi === currentModule ? 'active' : ''}" data-module="${mi}">
      <div class="slide-progress-bar" style="width: ${mi === currentModule ? progressPct : 0}%"></div>
      ${mod.slides.map((slide, si) => renderSlide(slide, si, mi)).join('')}
      <div class="slide-nav">
        <button class="nav-btn" onclick="prevSlide()" ${currentSlide === 0 ? 'disabled' : ''} aria-label="Previous slide">‚Üê</button>
        <div class="nav-center">
          <div class="slide-counter">${currentSlide + 1} / ${mod.slides.length}</div>
          <div class="progress-dots">
            ${mod.slides.map((_, i) => `<button class="progress-dot ${i === currentSlide ? 'active' : ''}" type="button" onclick="goToSlide(${i})" aria-label="Go to slide ${i + 1}" ${i === currentSlide ? 'aria-current="true"' : ''}></button>`).join('')}
          </div>
        </div>
        <button class="nav-btn" onclick="nextSlide()" aria-label="Next slide">‚Üí</button>
      </div>
      <div class="keyboard-hint" style="position:absolute;bottom:5px;left:50%;transform:translateX(-50%);font-size:0.6rem;opacity:0.4;">‚Üê ‚Üí arrows or swipe to navigate</div>
    </div>
  `;
  }).join('');
  document.getElementById('currentModule').textContent = MODULES[currentModule].title;
  updateSlideVisibility();
}

function renderSlide(slide, index, moduleIndex) {
  const theme = slide.theme || 'dark';
  let html = `<div class="slide ${theme} ${index === currentSlide ? 'active' : ''}" data-slide="${index}">`;

  switch(slide.type) {
    case 'title':
      html += `<div class="content"><h1 class="title gold animate">${slide.content.title}</h1><p class="subtitle animate delay-1">${slide.content.subtitle}</p></div>`;
      break;

    case 'objectives':
      html += `<div class="content">
        <div class="objectives-box animate">
          <div class="objectives-header">
            <div class="objectives-icon">üéØ</div>
            <div class="objectives-title">Learning Objectives</div>
          </div>
          <ul class="objectives-list">
            ${slide.content.objectives.map(obj => `<li>${obj}</li>`).join('')}
          </ul>
        </div>
        ${slide.content.tip ? `<p class="subtitle animate delay-1" style="font-size:0.85rem;max-width:600px">${slide.content.tip}</p>` : ''}
      </div>`;
      break;

    case 'story':
      html += `<div class="content">
        <article class="story-box ${slide.content.success ? 'success' : ''} animate" role="article">
          <div class="story-label">${slide.content.label}</div>
          ${slide.content.title ? `<h2 class="title gold" style="font-size:1.8rem;margin-bottom:0.75rem">${slide.content.title}</h2>` : ''}
          <p class="story-text">${slide.content.text}</p>
          ${slide.content.followup ? `<p class="story-text" style="margin-top:0.75rem;font-style:italic;opacity:0.9">${slide.content.followup}</p>` : ''}
        </article>
      </div>`;
      break;

    case 'stats':
      html += `<div class="content">
        ${slide.content.title ? `<h2 class="title gold animate">${slide.content.title}</h2>` : ''}
        ${slide.content.subtitle ? `<p class="subtitle animate delay-1">${slide.content.subtitle}</p>` : ''}
        <div class="stats-grid animate delay-2">
          ${slide.content.stats.map(s => `<div class="stat-box"><div class="stat-value gold">${s.value}</div><div class="stat-label">${s.label}</div></div>`).join('')}
        </div>
        ${slide.content.caption ? `<p class="subtitle animate delay-3" style="font-size:0.85rem;margin-top:0.75rem">${slide.content.caption}</p>` : ''}
      </div>`;
      break;

    case 'refrain':
      html += `<div class="content" style="justify-content:center;height:100%"><p class="refrain animate">"${slide.content.text}"</p></div>`;
      break;

    case 'concept':
      html += `<div class="content">
        <h2 class="title ${theme === 'light' ? 'navy' : 'gold'} animate">${slide.content.title}</h2>
        ${slide.content.subtitle ? `<p class="subtitle animate delay-1">${slide.content.subtitle}</p>` : ''}
        ${slide.content.text ? `<div class="card ${theme === 'light' ? '' : 'navy-bg'} animate delay-2"><p class="card-text">${slide.content.text}</p></div>` : ''}
        ${slide.content.highlight ? `<div class="story-box warning animate delay-3"><div class="story-label">Key Insight</div><p class="story-text">${slide.content.highlight}</p></div>` : ''}
        ${slide.content.checkpoints ? `
          <div class="timeline animate delay-2" style="margin-top:0.75rem">
            ${slide.content.checkpoints.map(cp => `
              <div class="timeline-item"><div class="timeline-days">${cp.day}</div><div class="timeline-content"><div class="timeline-title">${cp.event}</div></div></div>
            `).join('')}
          </div>
        ` : ''}
      </div>`;
      break;

    case 'checklist':
      html += `<div class="content">
        <h2 class="title gold animate">${slide.content.title}</h2>
        <div class="checklist animate delay-1">
          ${slide.content.items.map(item => `
            <div class="checklist-item">
              <div class="check-icon">‚úì</div>
              <div class="checklist-text">${item}</div>
            </div>
          `).join('')}
        </div>
      </div>`;
      break;

    case 'decision':
      const did = `dec_${moduleIndex}_${index}`;
      const answered = gameState.answeredQuestions[did];
      html += `<div class="content">
        <div class="decision-tree animate">
          <div class="decision-header">
            <div class="decision-icon">${slide.content.icon}</div>
            <div class="decision-title">${slide.content.title}</div>
            <div class="decision-xp">+${slide.content.xp} XP</div>
          </div>
          <div class="decision-scenario">${slide.content.scenario}</div>
          <div class="decision-question">${slide.content.question}</div>
          <div class="decision-options">
            ${slide.content.options.map(opt => {
              const isSelected = answered === opt.letter;
              const showCorrect = answered && opt.correct;
              const showIncorrect = answered && isSelected && !opt.correct;
              return `
                <div class="decision-option ${isSelected ? 'selected' : ''} ${showCorrect ? 'correct' : ''} ${showIncorrect ? 'incorrect' : ''} ${answered ? 'disabled' : ''}"
                     onclick="answerDecision('${did}', '${opt.letter}', ${opt.correct}, ${slide.content.xp})"
                     tabindex="0"
                     role="button"
                     aria-disabled="${answered ? 'true' : 'false'}">
                  <div class="option-letter">${opt.letter}</div>
                  <div class="option-text">${opt.text}</div>
                </div>
              `;
            }).join('')}
          </div>
          <div class="decision-feedback ${answered ? 'show' : ''} ${answered && slide.content.options.find(o => o.letter === answered)?.correct ? 'correct' : 'incorrect'}" role="alert" aria-live="polite">
            <div class="feedback-title">${answered && slide.content.options.find(o => o.letter === answered)?.correct ? '‚úì Correct!' : '‚úó Not quite'}</div>
            <div class="feedback-text">${answered && slide.content.options.find(o => o.letter === answered)?.correct ? slide.content.feedback.correct : slide.content.feedback.incorrect}</div>
          </div>
        </div>
      </div>`;
      break;

    case 'quiz':
      const qid = `quiz_${moduleIndex}_${index}`;
      const qAnswered = gameState.answeredQuestions[qid];
      html += `<div class="content">
        <div class="quiz-container animate">
          <div class="quiz-question">${slide.content.question}</div>
          <div class="quiz-options">
            ${slide.content.options.map((opt, oi) => {
              const isSelected = qAnswered === oi;
              const showCorrect = qAnswered !== undefined && opt.correct;
              const showIncorrect = qAnswered !== undefined && isSelected && !opt.correct;
              return `
                <div class="quiz-option ${showCorrect ? 'correct' : ''} ${showIncorrect ? 'incorrect' : ''} ${qAnswered !== undefined ? 'disabled' : ''}"
                     onclick="answerQuiz('${qid}', ${oi}, ${opt.correct}, ${slide.content.xp})"
                     tabindex="0"
                     role="button">
                  ${opt.text}
                </div>
              `;
            }).join('')}
          </div>
          <div class="quiz-feedback ${qAnswered !== undefined ? 'show' : ''} ${qAnswered !== undefined && slide.content.options[qAnswered]?.correct ? 'correct' : 'incorrect'}" role="alert" aria-live="polite">
            ${qAnswered !== undefined && slide.content.options[qAnswered]?.correct ? slide.content.feedback.correct : slide.content.feedback.incorrect}
          </div>
        </div>
      </div>`;
      break;
  }

  html += '</div>';
  return html;
}

function updateSlideVisibility() {
  const container = document.querySelector('.module-slides.active');
  if (!container) return;

  container.querySelectorAll('.slide').forEach((slide, i) => {
    slide.classList.toggle('active', i === currentSlide);
  });

  const progressBar = container.querySelector('.slide-progress-bar');
  if (progressBar) {
    const pct = ((currentSlide + 1) / MODULES[currentModule].slides.length) * 100;
    progressBar.style.width = pct + '%';
  }

  container.querySelector('.slide-counter').textContent = `${currentSlide + 1} / ${MODULES[currentModule].slides.length}`;
  container.querySelectorAll('.progress-dot').forEach((dot, i) => {
    dot.classList.toggle('active', i === currentSlide);
  });
  container.querySelector('.nav-btn').disabled = currentSlide === 0;
}

// ===== ANSWERS =====
function answerDecision(did, letter, correct, xp) {
  if (gameState.answeredQuestions[did] !== undefined) return;
  gameState.answeredQuestions[did] = letter;
  gameState.decisionsCompleted++;
  gameState.gradesAssigned = (gameState.gradesAssigned || 0) + 1;

  // Award first_grade badge on first decision
  if (gameState.decisionsCompleted === 1) awardBadge('first_grade');

  if (correct) {
    gameState.correctAnswers++;
    consecutiveCorrect++;
    addXP(xp);
    if (consecutiveCorrect >= 5) awardBadge('perfect_5');
    if (gameState.decisionsCompleted >= 15) awardBadge('decision_maker');
  } else {
    consecutiveCorrect = 0;
  }
  gameState.consecutiveCorrect = consecutiveCorrect;
  saveGame();
  renderSlides();
  updateComboDisplay();
  updateStatsDisplay();
}

function answerQuiz(qid, choice, correct, xp) {
  if (gameState.answeredQuestions[qid] !== undefined) return;
  gameState.answeredQuestions[qid] = choice;

  if (correct) {
    gameState.correctAnswers++;
    consecutiveCorrect++;
    addXP(xp);
    if (consecutiveCorrect >= 5) awardBadge('perfect_5');
  } else {
    consecutiveCorrect = 0;
  }
  gameState.consecutiveCorrect = consecutiveCorrect;
  saveGame();
  renderSlides();
  updateComboDisplay();
}

// ===== NAVIGATION =====
function goToModule(index) {
  if (index > 0 && !gameState.completedModules.includes(MODULES[index-1].id)) return;
  currentModule = index;
  currentSlide = 0;
  renderSlides();
  renderSidebar();
}

function goToSlide(index) {
  currentSlide = index;
  updateSlideVisibility();
}

function nextSlide() {
  const mod = MODULES[currentModule];
  if (currentSlide < mod.slides.length - 1) {
    currentSlide++;
    updateSlideVisibility();
  } else {
    completeModule();
  }
}

function prevSlide() {
  if (currentSlide > 0) {
    currentSlide--;
    updateSlideVisibility();
  }
}

function completeModule() {
  const mod = MODULES[currentModule];
  if (!gameState.completedModules.includes(mod.id)) {
    gameState.completedModules.push(mod.id);
    addXP(mod.xp);

    // Module-specific badges
    if (mod.id === 3) awardBadge('bias_hunter');
    if (mod.id === 4) awardBadge('consistency_king');
    if (mod.id === 5) awardBadge('directness_detective');
    if (mod.id === 6) awardBadge('precision_master');
    if (mod.id === 7) awardBadge('publication_sleuth');
    if (mod.id === 8) awardBadge('upgrader');
    if (mod.id === 10) awardBadge('grade_master');
    if (gameState.completedModules.length === MODULES.length) awardBadge('finisher');

    saveGame();
    triggerConfetti();
    updateCourseProgress();
  }

  if (currentModule < MODULES.length - 1) {
    goToModule(currentModule + 1);
  }
}

// ===== KEYBOARD =====
document.addEventListener('keydown', (e) => {
  const isRoleButton = e.target && e.target.getAttribute && e.target.getAttribute('role') === 'button';
  const isFormControl = e.target && e.target.closest && e.target.closest('button, a, input, textarea, select, [role="radio"], [role="option"]');
  if (isRoleButton || isFormControl) {
    if ((e.key === ' ' || e.key === 'Enter') && isRoleButton) { e.preventDefault(); e.target.click(); }
    return;
  }
  if (e.key === 'Escape') {
    closeBadgeModal();
    document.querySelector('.sidebar').classList.remove('open');
    document.getElementById('sidebarOverlay').classList.remove('show');
    return;
  }
  if (e.key === 'ArrowRight' || e.key === ' ') { e.preventDefault(); nextSlide(); }
  else if (e.key === 'ArrowLeft') { e.preventDefault(); prevSlide(); }
});

// Second keydown handler removed (first handler covers role="button" elements)

// ===== TOUCH =====
let touchStartX = 0;
document.addEventListener('touchstart', (e) => { touchStartX = e.changedTouches[0].screenX; }, { passive: true });
document.addEventListener('touchend', (e) => {
  const diff = touchStartX - e.changedTouches[0].screenX;
  if (Math.abs(diff) > 50) { diff > 0 ? nextSlide() : prevSlide(); }
}, { passive: true });

// ===== INIT =====
renderAll();
</script>
</body>
</html>
